



Synthesis of novel pyrazolic analogues of chalcones and their 3-aryl-4-(3-aryl-4,5-dihydro-1H-pyrazol-5-yl)-1-phenyl-1H-pyrazole derivatives as potential antitumor agents

Braulio Insuasty^{a,*}, Alexis Tigreros^a, Fabián Orozco^b, Jairo Quiroga^a, Rodrigo Abonía^a, Manuel Nogueras^{c,*}, Adolfo Sanchez^c, Justo Cobo^c

^aHeterocyclic Compounds Research Group, Department of Chemistry, Universidad del Valle, A. A. 25360, Cali, Colombia

^bDepartment of Chemistry, Universidad Nacional de Colombia, A. A. 14490, Bogotá D.C., Colombia

^cDepartment of Inorganic and Organic Chemistry, Universidad de Jaén, 23071 Jaén, Spain

ARTICLE INFO

Article history:

Received 8 March 2010

Revised 28 May 2010

Accepted 4 June 2010

Available online 9 June 2010

Keywords:

Claisen–Schmidt reaction

Pyrazolic chalcones

Functionalized dihydropyrazoles

Cyclocondensation reaction

Antitumoral agents

Microwave irradiation

ABSTRACT

Novel (*E*)-1-aryl-3-(3-aryl-1-phenyl-1H-pyrazol-4-yl)prop-2-en-1-ones **5/6** (pyrazolic chalcones) were synthesized from a Claisen–Schmidt reaction of 3-aryl-1-phenylpyrazol-4-carboxaldehydes **4** with several acetophenone derivatives **1**. Subsequently, the microwave-assisted cyclocondensation reaction of chalcones **5/6** with hydrazine afforded the new racemic 3-aryl-4-(3-aryl-4,5-dihydro-1H-pyrazol-5-yl)-1-phenyl-1H-pyrazoles **7** or their *N*-acetyl derivatives **8** and **9** when reactions were carried out in DMF or acetic acid, respectively. Several of these compounds were screened by the US National Cancer Institute (NCI) for their ability to inhibit 60 different human tumor cell lines, where **5c** and **9g** showed remarkable activity mainly against leukemia (K-562 and SR), renal cancer (UO-31) and non-small cell lung cancer (HOP-92) cell lines, with the most important GI₅₀ values ranging from 0.04 to 11.4 μM, from the in vitro assays.

© 2010 Elsevier Ltd. All rights reserved.

1. Introduction

The α,β-unsaturated ketones (chalcones) are considered to be precursors of flavonoids and isoflavonoids when found as naturally-occurring compounds, but it could be considered that their true importance is extended in two branches. The biological activity associated with them, including anti-inflammatory,^{1–3} antimitotic,⁴ anti-leishmanial,⁵ anti-invasive,^{6,7} anti-tuberculosis,⁸ anti-fungal,⁹ anti-malarial,^{10,11} anti-tumor, and anti-oxidant properties;¹² as well as their recognized synthetic utility in the preparation of pharmacologically-interesting heterocyclic systems like pyrazolines, which have also been largely studied owing to their pharmacological activities, which includes anti-tumor,¹³ anti-inflammatory,¹⁴ anti-parasitary,¹⁵ anti-depressive, anticonvulsant,¹⁶ antimicrobial,¹⁷ antinociceptives¹⁸ and nitric oxide synthase inhibitors, associated with diseases such as Alzheimer, Huntington, and inflammatory arthritis.¹⁹

On the other hand, microwave radiation has gained the attention of chemists during the last decades due to its unique advantages, such as shorter reaction times, cleaner reaction products, higher

yields and better selectivities, being a valuable alternative to accomplish more efficient syntheses of a variety of organic compounds with a considerable simplicity of operation and milder reaction conditions, when combined with the solvent-free approach, as it provides an opportunity to work with open vessels.^{20–28}

In this way, targeting the preparation of the mentioned nitrogen containing heterocycles, we report herein the regioselective synthesis and cytotoxic activities of (*E*)-1-aryl-3-(3-aryl-1-phenyl-1H-pyrazol-4-yl)prop-2-en-1-ones **5/6a–h** (pyrazolic chalcones) and 3-aryl-4-(3-aryl-4,5-dihydro-1H-pyrazol-5-yl)-1-phenyl-1H-pyrazoles **7a–h** and their *N*-acetyl derivatives **8/9a–h** by using microwave-assisted reaction conditions. Compounds **7a–h** and **8/9a–h** were obtained as racemic mixtures in all cases.

2. Results and discussion

2.1. Chemistry

In order to obtain the pyrazolic chalcones, the corresponding 4-formylpyrazolic precursors **4** were initially synthesized from the phenylhydrazones **3** (prepared by condensation of the respective acetophenones **1** and phenylhydrazine **2**); following a similar procedure described by Kira et al.²⁹ In this sense, the Vilsmeier–

* Corresponding authors. Fax: +57 2 33392440 (B.I.); +34 953211876 (M.N.).


E-mail addresses: brainsu@univalle.edu.co (B. Insuasty), mmontiel@ujaen.es (M. Nogueras).

Haack reagent (POCl_3/DMF) was employed affording compounds **4** in 75–78% yield (Scheme 1). Compounds **4** were characterized by using IR, NMR, and MS techniques. Their analytical and spectroscopic data agreed with those reported in the literature²⁹ for the same compounds. Subsequently, the Claisen–Schmidt condensation of the obtained aldehydes **4** with the acetophenones **1a–h** afforded the corresponding pyrazolic chalcones **5/6a–h**, (Scheme 1).


The structure elucidation of compounds **5/6a–h** was based on the spectral data (IR, ^1H NMR, ^{13}C NMR, and mass spectrometry). The IR spectra showed mainly absorption bands at 1662–1626 and 1521–1606 cm^{-1} assigned to ($\text{C}=\text{O}$, $\text{C}=\text{N}$) and ($\text{C}=\text{C}$) functionalities, respectively. Particularly, the derivatives **5a–h** and **6a** showed typical absorption bands at 1337–1508 cm^{-1} due to their NO_2 stretching vibrations. In the ^1H NMR spectra of products **5/6** the H-6 and H-7 appears each one as a doublet at $\delta = 7.67$ –7.87 ppm and $\delta = 7.60$ –7.69 ppm, respectively, with coupling constant between them of $^3J = 13.0$ –15.9 Hz, which agrees with a *trans* configuration. Analysis of ^{13}C , DEPT-135 and 2D-heteronuclear NMR spectra (HSQC and HMBC) provided the final structural elucidation of compounds **5** and **6**. Thus, the signal for C-6 is in the range of δ 118.6–123.5 ppm, the signal for C-7 appears at δ 132.1–134.8 ppm, while the $\text{C}=\text{O}$ carbon atom appears at δ 186.8–189.0 ppm. Finally, the mass spectra of compounds **5/6** showed well-defined molecular ions with a characteristic fragmentation pattern involving the loss of the phenyl group in all cases.

Continuing with the synthetic approach, the microwave irradiation of a mixture of the chalcones **5a–h** (1.0 mmol) and hydrazine (1.3 mmol) in the presence of DMF as solvent (0.2 mL), afforded the desired products **7a–h** in good yields (Scheme 2). When the same reaction was carried out starting with chalcones **5/6a–h** in the presence of acetic acid (0.5 mL) instead of DMF, formation of different products was observed and identified as the corresponding *N*-acetyl derivatives **8/9a–h** (Scheme 2). This finding suggests that the acetic acid acted not only as solvent but also as acetylating agent.

Compounds **7–9** were obtained as racemic mixtures and were fully characterized by detailed (IR, NMR, and MS) measurements (Section 4). The IR spectra showed the expected absorption bands between 3289–3309 and 1600–1676 cm^{-1} corresponding to the NH functionality for products **7** and to the $\text{C}=\text{O}$ functionality for products **8/9**, respectively. In the ^1H NMR spectra of compounds **7–9** the two methylenic 4'-H protons and the stereogenic 5'-H proton of the pyrazolinic moiety form an ABX spin system.



Scheme 1. Synthesis of the novel pyrazolic chalcones **5/6a–h**.



Scheme 2. Synthesis of the new pyrazoles **7a–h** and their *N*-acetyl derivatives **8/9a–h**.

Thus, the 4'-H_A and 4'-H_B appear each one as a double-doublet at $\delta = 2.94$ –3.28 ppm and $\delta = 3.44$ –3.95 ppm, respectively, with $^2J_{AB} = 16.1$ –18.0 Hz., while 5'-H appears as a double-doublet at $\delta = 5.08$ –5.82 ppm with $^3J_{AX} = 10.1$ –11.0 Hz for **7**, $^3J_{AX} = 5.4$ –5.6 Hz for **8/9** and $^3J_{BX} = 10.8$ –13.4 Hz for **7–9**. The NH protons of compounds **7** were not observed except for **7b** which appears as a singlet at $\delta = 7.19$ ppm. The main signals in the ^{13}C NMR for compounds **7–9** correspond to C-4' at δ 39.5–42.2 ppm, C-5' at δ 51.4–55.7 ppm and the quaternary C-3' at δ 148.2–153.3 ppm. Finally, mass spectra of compounds **7–9** showed also well-defined molecular ions.

2.2. Anticancer activity

The two-stage screening process started with the evaluation of eight compounds (**5c**, **6b**, **6g**, **7b**, **7g**, **8c**, **9d**, and **9g**) selected by NCI, against the 60 cell lines at a single dose of 1.0 μM . The output from the single dose screen was reported as a mean graph available for analysis by the COMPARE program. The results of the primary assay showed that compounds **6b**, **6g**, **7b**, **7g**, **8c**, and **9d** were essentially inactive, while compounds **5c** and **9g** were declared active (Table 1).

Subsequently, a secondary screening process was performed, in order to determine the cytostatic activity of such compounds, against the 60 cell panel representing leukemia, melanoma and

Table 1
Results of primary anticancer assay for eight compounds selected by the NCI

Compound	Activity ^a
5c	A
6b	NA
6g	NA
7b	NA
7g	NA
8c	NA
9d	NA
9g	A

^a Activity denoted as: A = active; NA = not active.

Table 2

In vitro testing expressed as growth inhibition of cancer cell lines for compounds **5c** and **9g**^a

Panel/cell line	Compounds			
	5c		9g	
	GI ₅₀ ^b (μM)	LC ₅₀ ^c (μM)	GI ₅₀ ^b (μM)	LC ₅₀ ^c (μM)
<i>Leukemia</i>				
RPMI-8226	1.86	>100	1.73	>100
SR	2.76	>100	1.57	8.06
CCRF-CEM	—	>100	—	—
HL-60(TB)	>100	>100	—	—
K-562	0.09	>100	—	—
MOLT-4	0.87	>100	—	—
<i>Non-small cell lung cancer</i>				
EKVX	4.97	>100	—	>100
HOP-62	26.0	>100	—	—
NCI-H226	3.77	>100	—	>100
NCI-H23	4.99	>100	1.77	—
NCI-H460	—	>100	1.98	—
NCI-H522	6.41	>100	2.20	>100
HOP-92	—	>100	0.04	—
NCI-H322M	—	>100	—	>100
A549/ATCC	—	>100	—	>100
<i>Colon</i>				
COLO 205	2.09	—	2.16	—
HCT-116	2.75	>100	1.94	—
HCT-15	—	>100	3.09	>100
HT29	—	>100	—	>100
KM12	—	>100	—	>100
SW-620	—	—	3.48	>100
HCC-2998	>100	>100	2.21	>100
<i>CNS</i>				
SF-295	2.32	74.1	2.48	>100
SF-539	3.95	>100	1.87	—
U251	2.09	>100	1.71	—
SF-268	3.12	>100	4.55	>100
SNB-19	4.90	>100	—	>100
SNB-75	1.55	24.0	2.76	>100
<i>Melanoma</i>				
LOX IMVI	—	>100	1.66	—
MALME-3M	2.44	>100	—	>100
MDA-MB-435	—	>100	—	>100
SK-MEL-5	>100	>100	1.79	—
UACC-257	>100	>100	>100	>100
UACC-62	11.4	>100	2.40	>100
SK-MEL-2	6.99	57.9	—	>100
M14	—	>100	—	>100
SK-MEL-28	—	>100	—	>100
<i>Ovarian</i>				
IGROV1	3.54	>100	—	>100
OVCAR-3	1.96	>100	—	—
OVCAR-4	—	—	—	>100
NCI/ADR-RES	4.64	>100	1.80	—
OVCAR-8	6.32	>100	—	>100
OVCAR-5	>100	>100	1.81	>100
SK-OV-3	12.5	>100	2.14	>100
<i>Renal</i>				
A498	3.14	>100	—	>100
ACHN	4.27	>100	1.82	—
CAKI-1	4.56	>100	1.96	—
RXF 393	2.08	9.87	1.82	—
SN12C	—	>100	—	>100
TK-10	3.12	>100	—	>100
UO-31	0.10	>100	—	>100
786-0	3.94	>100	—	—
<i>Prostate</i>				
DU-145	—	>100	—	>100
PC-3	—	—	2.35	>100
<i>Breast</i>				
MCF7	—	>100	—	>100
MDA-MB-231/ATCC	2.45	>100	1.88	—
BT-549	2.25	>100	—	>100
T-47D	1.12	>100	1.90	—

Table 2 (continued)

Panel/cell line	Compounds			
	5c		9g	
	GI ₅₀ ^b (μM)	LC ₅₀ ^c (μM)	GI ₅₀ ^b (μM)	LC ₅₀ ^c (μM)
MDA-MB-468	2.91	>100	—	>100
HS 578T	2.55	>100	—	>100

^a Data obtained from NCI's in vitro disease-oriented human tumor cell lines screen.^{31–33}

^b GI₅₀ was the drug concentration resulting in a 50% reduction in the net protein increase (as measured by SRB staining) in control cells during the drug incubation. Determined at five concentration levels (100, 10, 1.0, 0.1, and 0.01 μM).

^c LC₅₀ is a parameter of cytotoxicity and reflects the molar concentration needed to kill 50% of the cells.

cancers of the lung, colon, brain, ovary, breast, prostate, and kidney; where the testing results were expressed according to the next three parameters: GI₅₀ which is the molar concentration of the compounds required to inhibit the growth of that cell line by 50% (relative to untreated cells). TGI as the molar concentration that causes total growth inhibition, and LC₅₀ which is a parameter of cytotoxicity and reflects the molar concentration needed to kill 50% of the cells.³⁰ The compounds were evaluated at five concentration levels (100, 10, 1.0, 0.1, and 0.01 μM) and the test consisted of a 48 h continuous drug exposure protocol using sulforhodamide B (SRB) protein assay to estimate cell growth. Details of this evaluation method, and the complementary information related with the activity pattern over all cell lines, have been published.^{31–33} As shown in Table 2, compound **5c** presented remarkable activity against 37 human tumor cell lines, being the most sensitive to growth inhibition K-562 of leukemia panel with GI₅₀ value of 0.09 μM and UO-31 of renal cancer panel displaying a GI₅₀ value of 0.10 μM (citotoxicity expressed as LC₅₀ with values >100 μM for both cell lines). Likewise, compound **9g** (active against 28 human tumor cell lines) was found especially effective against the cell line HOP-92 of non-small cell lung cancer panel exhibiting a remarkable GI₅₀ value of 0.04 μM (LC₅₀ >100 μM), as well as a GI₅₀ of 1.57 μM (LC₅₀ >100 μM) for cell line SR of leukemia panel. In summary, derivatives **5c** and **9g** showed significant activities with GI₅₀ ranges of 0.09–26.0 μM and 0.04–4.55 μM, respectively; where most of the GI₅₀ values of the screening process resulted in a sensitive range inferior of 20 μM denoting an outstanding activity in both cases. The values of cytotoxicity associated with compounds **5c** and **9g** and measured as LC₅₀ are in most of the cell lines >100 μM (Table 2).

3. Conclusion

As a part of our current research work focused on the development of new bioactive heterocyclic compounds, the synthesis and anticancer screening of the novel pyrazolic chalcones **5/6a–h**, pyrazoles **7a–h** and their *N*-acetyl derivatives **8/9a–h** have been performed. The anticancer evaluation data revealed that among the eight compounds studied, derivatives **5c** and **9g** exhibited high activity patterns against different cancer cell lines with remarkable values in panels of non-small cell lung cancer, leukemia, and renal cancer. Owing to the significant results obtained, chemical studies are being conducted to improve the antitumor activity of such compounds, as well as other biological studies focused on antiviral and antifungal activity.

4. Experimental

Melting points were determined on a Buchi Melting Point Apparatus and are uncorrected. IR spectra were performed on a Shimadzu FTIR 8400 spectrometer in KBr disks. The ¹H and ¹³C

NMR spectra were run on a Bruker DPX 400 spectrometer operating at 400 MHz and 100 MHz, respectively, using DMSO- d_6 as solvent and TMS as internal standard. The mass spectra were obtained on a Hewlett Packard HP Engine-5989 spectrometer (equipped with a direct inlet probe) operating at 70 eV. The elemental analyses were carried out on a LECO CHNS-900 elemental analyzer. Reactions under microwave irradiation were performed using a CEM Discover™ monomode system with power/time control using a ramp of 100–300 W.

4.1. General procedure for the synthesis of the pyrazolic chalcones 5/6a–h

To a solution of 3-aryl-1-phenylpyrazol-4-carboxaldehyde **4** (1.0 mmol), acetophenone **1** (1.0 mmol) and ethanol (30.0 mL), a pellet of KOH was added. The reaction mixture was stirred at ambient temperature until formation of a precipitate. The solid obtained was isolated by filtration, washed and recrystallized from a (1:1) EtOH/DMF mixture.

4.1.1. (E)-1-(4-Nitrophenyl)-3-[3-(4-nitrophenyl)-1-phenyl-1H-pyrazol-4-yl]prop-2-en-1-one (5a)

Green solid, 76% yield; mp: 244 °C. FTIR (KBr) ν (cm^{-1}): 1661 (C=O and C=N); 1517 and 1342 (NO_2); 1584 (C=C); ^1H NMR (400 MHz, DMSO- d_6) δ 7.41 (t, 1H, H_{pA} , J = 7.14 Hz), 7.56 (t, 2H, H_{mA} , J = 8.20 Hz), 7.61 (d, 1H, H-7, 15.51 Hz), 7.68 (d, 1H, H-6, 15.30 Hz), 7.92 (d, 2H, H_{oA} , J = 7.05 Hz), 7.97 (d, 2H, H_{oB} , J = 8.89 Hz), 7.98 (d, 2H, H_{oC} , J = 8.55 Hz), 8.25 (d, 2H, H_{mC} , J = 8.60 Hz), 8.30 (d, 2H, H_{mB} , J = 8.88 Hz), 9.19 (s, 1H, H-5) ppm; ^{13}C NMR (100 MHz, DMSO- d_6) δ 117.1 (C-4), 122.7 (C-6), 123.3 (C_{mB}), 126.3 (C_{pA}), 126.6 (C_{oA}), 128.3 (C_{mA}), 128.6 (C_{oB}), 128.7 (C_{oC}), 128.9 (C-5), 129.3 (C_{mC}), 134.8 (C-7), 136.3 (C_{iC}), 137.6 (C_{iA}), 138.4 (C_{iB}), 144.4 (C_{pC}), 147.2 (C_{pB}), 149.8 (C-3), 188.6 (C-8) ppm. MS (70 eV) m/z (%): 440 (12, M^+), 279 (100), 77 (39). Anal. Calcd for $\text{C}_{24}\text{H}_{16}\text{N}_4\text{O}_5$: C, 65.45; H, 3.66; N, 12.77. Found: C, 65.54; H, 3.70; N, 12.69.

4.1.2. (E)-1-(4-Fluorophenyl)-3-[3-(4-nitrophenyl)-1-phenyl-1H-pyrazol-4-yl]prop-2-en-1-one (5b)

Yellow solid, 76% yield; mp: 221 °C. FTIR (KBr) ν (cm^{-1}): 1659 (C=O and C=N); 1602 (C=C); 1507 and 1343 (NO_2); ^1H NMR (400 MHz, DMSO- d_6) δ 6.61 (d, 2H, H_{oC} , J = 8.89 Hz), 7.41 (t, 1H, H_{pA} , J = 8.89 Hz), 7.59 (t, 2H, H_{mA} , J = 7.86 Hz), 7.68 (d, 1H, H-7, J = 15.51 Hz), 7.87 (d, 1H, H-6, J = 15.30 Hz), 7.93 (d, 2H, H_{oA} , J = 8.40 Hz), 7.95 (d, 2H, H_{oB} , J = 8.88 Hz), 8.17 (d, 2H, H_{mC} , J = 8.89 Hz), 8.37 (d, 2H, H_{mB} , J = 8.89 Hz), 9.42 (s, 1H, H-5) ppm. ^{13}C NMR (100 MHz, DMSO- d_6) δ 115.8 (C_{oC}), 118.7 (C-4), 122.0 (C-6), 124.0 (C_{mB}), 126.8 (C_{oA}), 127.5 (C_{pA}), 129.2 (C_{oB}), 129.3 (C-5), 129.7 (C_{mA}), 131.1 (C_{mC}), 133.3 (C-7), 138.3 (C_{iB}), 138.8 (C_{iA}), 147.2 (C_{pB}), 150.3 (C-3), 163.7 (C_{pC}), 166.2 (C_{iC}), 187.0 (C-8) ppm. MS (70 eV) m/z (%): 413 (32, M^+), 244 (65), 123 (100), 77 (56). Anal. Calcd for $\text{C}_{24}\text{H}_{16}\text{FN}_3\text{O}_3$: C, 69.73; H, 3.90; N, 10.16. Found: C, 69.70; H, 3.95; N, 10.18.

4.1.3. (E)-1-(4-Chlorophenyl)-3-[3-(4-nitrophenyl)-1-phenyl-1H-pyrazol-4-yl]prop-2-en-1-one (5c)

Yellow solid, 91% yield; mp: 224 °C. FTIR (KBr) ν (cm^{-1}): 1660 (C=O and C=N); 1600 (C=C); 1507 and 1350 (NO_2); ^1H NMR (400 MHz, DMSO- d_6) δ 7.42 (t, 1H, H_{pA} , J = 7.03 Hz), 7.55 (d, 2H, H_{mA} , J = 7.03 Hz), 7.57 (d, 2H, H_{oA} , J = 6.82 Hz), 7.60 (d, 1H, H-7, J = 13.24 Hz), 7.67 (d, 1H, H-6, J = 13.03 Hz), 7.93 (d, 2H, H_{oC} , J = 7.63 Hz), 7.96 (d, 2H, H_{oB} , J = 8.89 Hz), 8.01 (d, 2H, H_{mC} , J = 8.01 Hz), 8.33 (t, 2H, H_{mB} , J = 8.89 Hz), 9.17 (s, 1H, H-5) ppm. ^{13}C NMR (100 MHz, DMSO- d_6) δ 117.8 (C-4), 118.6 (C-6), 122.4 (C_{oC}), 123.1 (C_{mB}), 126.7 (C_{pA}), 126.8 (C_{oA}), 128.6 (C_{oB}), 128.8 (C-5), 129.0 (C_{mA}), 129.3 (C_{mC}), 133.0 (C-7), 136.0 (C_{iC}), 137.3

(C_{pC}), 138.0 (C_{iB}), 138.5 (C_{iA}), 147.2 (C_{pB}), 149.7 (C-3), 187.5 (C-8) ppm. MS (70 eV) m/z (%): 429 (13, M^+), 244 (61), 139 (100), 77 (90). Anal. Calcd for $\text{C}_{24}\text{H}_{16}\text{ClN}_3\text{O}_3$: C, 67.12; H, 3.79; N, 9.69. Found: C, 67.20; H, 3.85; N, 9.74.

4.1.4. (E)-1-(4-Bromophenyl)-3-[3-(4-nitrophenyl)-1-phenyl-1H-pyrazol-4-yl]prop-2-en-1-one (5d)

Yellow solid, 95% yield; mp: 220 °C. FTIR (KBr) ν (cm^{-1}): 1660 (C=O and C=N); 1599 (C=C); 1508 and 1352 (NO_2); ^1H NMR (400 MHz, DMSO- d_6) δ 7.41 (t, 1H, H_{pA} , J = 7.65 Hz), 7.72 (d, 2H, H_{oC} , J = 8.27 Hz), 7.56 (t, 2H, H_{mA} , J = 7.24 Hz), 7.62 (d, 1H, H-7, J = 15.50 Hz), 7.80 (d, 1H, H-6, J = 15.7 Hz), 7.93 (d, 2H, H_{oA} , J = 8.48 Hz), 7.95 (d, 2H, H_{mC} , J = 8.30 Hz), 7.96 (d, 2H, H_{oB} , J = 7.92 Hz), 8.33 (d, 2H, H_{mB} , J = 7.96 Hz), 9.16 (s, 1H, H-5) ppm. ^{13}C NMR (100 MHz, DMSO- d_6) δ 117.8 (C-4), 123.1 (C_{mB}), 122.4 (C-6), 126.2 (C_{pC}), 126.8 (C_{pA}), 128.6 (C_{oB}), 128.8 (C-5), 128.9 (C_{oA}), 129.4 (C_{mC}), 129.7 (C_{mA}), 131.0 (C_{oC}), 133.1 (C-7), 136.4 (C_{iC}), 138.0 (C_{iB}), 138.5 (C_{iA}), 147.2 (C_{pB}), 149.7 (C-3), 187.7 (C-8) ppm. MS (70 eV) m/z (%): 473 (7, M^+), 183 (100), 244 (57), 77 (70). Anal. Calcd for $\text{C}_{24}\text{H}_{16}\text{BrN}_3\text{O}_3$: C, 60.77; H, 3.40; N, 8.86. Found: C, 60.80; H, 3.48; N, 8.79.

4.1.5. (E)-3-[3-(4-Nitrophenyl)-1-phenyl-1H-pyrazol-4-yl]-1-phenylprop-2-en-1-one (5e)

Yellow solid, 92% yield; mp: 190 °C. FTIR (KBr) ν (cm^{-1}): 1626 (C=O and C=N), 1595 (C=C), 1507 and 1339 (NO_2); ^1H NMR (400 MHz, DMSO- d_6) δ 7.42 (t, 1H, H_{pA} , J = 7.00 Hz), 7.49 (d, 2H, H_{mC} , J = 7.56 Hz), 7.55 (t, 2H, H_{mA} , J = 7.15 Hz), 7.60 (t, 1H, H_{pC} , J = 8.15 Hz), 7.62 (d, 1H, H-7, J = 15.35 Hz), 7.67 (d, 1H, H-6, J = 15.30 Hz), 7.91 (d, 2H, H_{oA} , J = 7.40 Hz), 7.96 (d, 2H, H_{oB} , J = 7.40 Hz), 7.98 (d, 2H, H_{oC} , J = 8.15 Hz), 8.32 (d, 2H, H_{mB} , J = 7.39 Hz), 9.15 (s, 1H, H-5) ppm. ^{13}C NMR (100 MHz, DMSO- d_6) δ 118.0 (C-4), 123.0 (C-6), 124.1 (C_{mB}), 126.0 (C_{oC}), 126.3 (C_{pA}), 127.4 (C_{pC}), 127.8 (C-5), 128.0 (C_{oA}), 128.3 (C_{mA}), 128.7 (C_{oB}), 129.6 (C_{mC}), 133.1 (C-7), 135.0 (C_{iC}), 137.9 (C_{iB}), 139.0 (C_{iA}), 147.6 (C_{pB}), 149.7 (C-3), 189.0 (C-8) ppm. MS (70 eV) m/z (%): 395 (36, M^+), 119 (100), 77 (78). Anal. Calcd for $\text{C}_{24}\text{H}_{17}\text{N}_3\text{O}_3$: C, 72.90; H, 4.33; N, 10.63. Found: C, 72.98; H, 4.33; N, 10.59.

4.1.6. (E)-1-(4-Methylphenyl)-3-[3-(4-nitrophenyl)-1-phenyl-1H-pyrazol-4-yl]prop-2-en-1-one (5f)

Yellow solid, 89% yield; mp: 214 °C. FTIR (KBr) ν (cm^{-1}): 1661 (C=O and C=N), 1596 (C=C), 1509 and 1350 (NO_2); ^1H NMR (400 MHz, DMSO- d_6) δ 2.40 (s, 3H, H-CH₃), 7.34 (d, 2H, H_{mC} , J = 7.65 Hz), 7.40 (t, 1H, H_{pA} , J = 7.45 Hz), 7.56 (t, 2H, H_{mA} , J = 7.45 Hz), 7.64 (d, 1H, H-7, J = 15.51 Hz), 7.69 (d, 1H, H-6, J = 15.92 Hz), 7.91 (d, 2H, H_{oC} , J = 7.60 Hz), 7.93 (d, 2H, H_{oA} , J = 8.30 Hz), 7.96 (d, 2H, H_{oB} , J = 7.31 Hz), 8.33 (d, 2H, H_{mB} , J = 7.24 Hz), 9.15 (s, 1H, H-5) ppm. ^{13}C NMR (100 MHz, DMSO- d_6) δ 20.3 (C-CH₃), 117.9 (C-4), 118.6 (C_{oC}), 122.9 (C-6), 123.1 (C_{mB}), 126.7 (C_{pA}), 127.6 (C_{oA}), 128.5 (C_{mC}), 128.6 (C_{oB}), 128.7 (C-5), 128.8 (C_{mA}), 132.1 (C-7), 134.9 (C_{pC}), 138.1 (C_{iB}), 138.5 (C_{iA}), 142.5 (C_{iC}), 147.1 (C_{pB}), 149.6 (C-3), 188.0 (C-8) ppm. MS (70 eV) m/z (%): 409 (38, M^+), 244 (28), 119 (100), 77 (31). Anal. Calcd for $\text{C}_{25}\text{H}_{19}\text{N}_3\text{O}_3$: C, 73.34; H, 4.68; N, 10.26. Found: C, 73.44; H, 4.70; N, 10.16.

4.1.7. (E)-1-(4-Methoxyphenyl)-3-[3-(4-nitrophenyl)-1-phenyl-1H-pyrazol-4-yl]prop-2-en-1-one (5g)

Yellow solid, 75% yield; mp: 205 °C. FTIR (KBr) ν (cm^{-1}): 1657 (C=O and C=N), 1599 (C=C), 1507 and 1347 (NO_2), 1222 (O-CH₃); ^1H NMR (400 MHz, DMSO- d_6) δ 3.87 (s, 3H, H-OCH₃), 7.08 (d, 2H, H_{mC} , J = 9.10 Hz), 7.41 (t, 1H, H_{pA} , J = 7.44 Hz), 7.58 (t, 2H, H_{mA} , J = 8.48 Hz), 7.67 (d, 1H, H-7, J = 15.51 Hz), 7.87 (d, 1H, H-6, J = 15.28 Hz), 7.94 (d, 2H, H_{oC} , J = 9.12 Hz), 7.95 (d, 2H, H_{oA} , J = 8.48 Hz), 8.08 (d, 2H, H_{oB} , J = 9.10 Hz), 8.37 (d, 2H, H_{mB} , J = 9.10 Hz), 9.17 (s, 1H, H-5) ppm. ^{13}C NMR (100 MHz, DMSO- d_6)

δ 55.6 (C–OCH₃), 114.0 (C_mC), 117.8 (C-4), 122.3 (C_mB), 122.4 (C-6), 124.1 (C_oC), 127.0 (C_oA), 128.0 (C-5), 129.0 (C_oB), 129.5 (C_mA), 129.7 (C_iC), 132.2 (C_pA), 133.3 (C-7), 137.6 (C_iA), 138.2 (C_iB), 146.1 (C_pB), 149.7 (C-3), 163.8 (C_pC), 188.6 (C-8) ppm. MS (70 eV) m/z (%): 425 (9, M⁺), 135 (100), 77 (45). Anal. Calcd for C₂₅H₁₉N₃O₄: C, 70.58; H, 4.50; N, 9.88. Found: C, 70.65; H, 4.48; N, 9.85.

4.1.8. (E)-1-(3,4-Methylenedioxyphenyl)-3-[3-(4-nitrophenyl)-1-phenyl-1H-pyrazol-4-yl]prop-2-en-1-one (5h)

Green solid, 80% yield; mp: 169 °C. FTIR (KBr), ν (cm⁻¹): 1657 (C=O and C=N), 1598 (C=C), 1507 and 1347 (NO₂), 1264 y 1102 (O–CH₂–O); ¹H NMR (400 MHz, DMSO-*d*₆) δ 6.07 (s, 2H, H–CH₂), 6.98 (d, 2H, H_mC, *J* = 8.03 Hz), 7.39 (t, 1H, H_pA, *J* = 7.53 Hz), 7.47 (s, 1H, H_oC), 7.54 (t, 2H, H_mA, *J* = 7.53 Hz), 7.60 (d, 1H, H-7, *J* = 15.48), 7.63 (d, 1H, H-6, *J* = 15.57), 7.66 (d, 2H, H_oC, *J* = 8.03 Hz), 7.88 (d, 2H, H_oA, *J* = 7.78 Hz), 7.91 (d, 2H, H_oB, *J* = 8.78 Hz), 8.31 (d, 2H, H_mB, *J* = 8.79 Hz), 9.11 (s, 1H, H-5) ppm. ¹³C NMR (100 MHz, DMSO-*d*₆) δ 102.4 (C–CH₂), 108.5 (C_mC), 119.0 (C-4), 119.6 (C_oA), 123.5 (C-6), 124.3 (C_mB), 125.1 (C_oC), 127.9 (C_pA), 129.4 (C_oC), 129.6 (C_oB), 129.7 (C-5), 130.0 (C_mA), 132.8 (C_iC), 132.9 (C-7), 138.2 (C_pC), 139.1 (C_pB), 139.4 (C_iA), 148.1 (C_iB), 148.5 (C-3), 150.7 (C_mC), 187.7 (C-8) ppm. MS (70 eV) m/z (%): 439 (11, M⁺), 279 (100), 149 (100), 77 (44). Anal. Calcd for C₂₅H₁₇N₃O₅: C, 68.33; H, 3.90; N, 9.56. Found: C, 68.28; H, 3.88; N, 9.58.

4.1.9. (E)-3-[3-(4-Chlorophenyl)-1-phenyl-1H-pyrazol-4-yl]-1-(4-nitrophenyl)-prop-2-en-1-one (6a)

Green solid, 88% yield; mp: 234 °C. FTIR (KBr), ν (cm⁻¹): 1662 (C=O and C=N), 1521 and 1348 (NO₂), 1521 (C=C); ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.39 (t, 1H, H_pA, *J* = 6.61 Hz), 7.55 (t, 2H, H_mA, *J* = 8.27 Hz), 7.57 (d, 2H, H_oB, *J* = 8.06 Hz), 7.60 (d, 1H, H-7, 15.50 Hz), 7.69 (d, 2H, H_mB, *J* = 8.48 Hz), 7.70 (d, 1H, H-6, 15.70 Hz), 7.91 (d, 2H, H_oA, *J* = 7.65 Hz), 8.17 (d, 2H, H_oC, *J* = 8.68 Hz), 8.32 (d, 2H, H_mC, *J* = 8.89 Hz), 9.15 (s, 1H, H-5) ppm. ¹³C NMR (DMSO-*d*₆) δ 117.13 (C-4), 118.5 (C_oA), 121.7 (C-6), 122.9 (C_mC), 126.6 (C_pA), 128.1 (C_oB), 128.7 (C_oC), 128.8 (C-5), 128.9 (C_mA), 129.3 (C_mB), 130.4 (C_iB), 133.15 (C_pB), 134.8 (C-7), 138.5 (C_iA), 142.4 (C_iC), 149.4 (C_pC), 151.1 (C-3), 187.8 (C-8) ppm. MS (70 eV) m/z (%): 429 (8, M⁺), 279 (100), 77 (60). Anal. Calcd for C₂₄H₁₆ClN₃O₃: C, 67.06; H, 3.75; N, 9.78. Found: C, 67.19; H, 3.70; N, 9.77.

4.1.10. (E)-3-[3-(4-Chlorophenyl)-1-phenyl-1H-pyrazol-4-yl]-1-(4-fluorophenyl)-prop-2-en-1-one (6b)

Yellow solid, 75% yield; mp: 166 °C. FTIR (KBr), ν (cm⁻¹): 1660 (C=O and C=N), 1600 (C=C); ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.42 (t, 1H, H_pA, *J* = 8.69 Hz), 7.44 (d, 2H, H_oC, *J* = 8.89 Hz), 7.60 (t, 2H, H_mA, *J* = 8.48 Hz), 7.64 (d, 2H, H_oB, *J* = 7.44 Hz), 7.68 (d, 1H, H-7, *J* = 15.3 Hz), 7.70 (d, 2H, H_oA, *J* = 8.68 Hz), 7.87 (d, 1H, H-6, *J* = 15.5 Hz), 7.94 (d, 2H, H_mB, *J* = 7.45 Hz), 8.17 (d, 2H, H_mC, *J* = 8.89 Hz), 9.41 (s, 1H, H-5) ppm. ¹³C NMR (100 MHz, DMSO-*d*₆) δ 115.8 (C_oC), 117.8 (C-4), 118.7 (C_mB), 121.4 (C-6), 127.3 (C_pA), 128.7 (C_oB), 128.9 (C-5), 129.7 (C_mA), 130.0 (C_oA), 130.7 (C_iB), 131.1 (C_mC), 133.9 (C-7), 134.3 (C_pB), 138.8 (C_iA), 151.6 (C-3), 163.7 (C_iC), 166.2 (C_pC), 187.2 (C-8) ppm. MS (70 eV) m/z (%): 402 (9, M⁺), 279 (100), 77 (49). Anal. Calcd for C₂₄H₁₆ClFN₃O: C, 71.55; H, 4.00; N, 6.95. Found: C, 71.50; H, 3.96; N, 6.99.

4.1.11. (E)-1-(4-Chlorophenyl)-3-[3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl]prop-2-en-1-one (6c)

Yellow solid, 90% yield; mp: 185 °C. FTIR (KBr), ν (cm⁻¹): 1660 (C=O and C=N), 1598 (C=C); ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.42 (t, 1H, H_pA, *J* = 7.03 Hz), 7.58 (t, 2H, H_mA, *J* = 8.47 Hz), 7.62 (d, 2H, H_oB, *J* = 7.47 Hz), 7.65 (d, 2H, H_oC, *J* = 8.69 Hz), 7.68 (d, 1H, H-7,

J = 15.50 Hz), 7.70 (d, 2H, H_oA, *J* = 7.86 Hz), 7.84 (d, 1H, H-6, *J* = 15.51 Hz), 7.94 (d, 2H, H_mB, *J* = 8.47 Hz), 8.10 (d, 2H, H_mC, *J* = 8.68 Hz), 9.41 (s, 1H, H-5) ppm. ¹³C NMR (100 MHz, DMSO-*d*₆) δ 117.8 (C-4), 118.7 (C-6), 121.2 (C_mB), 127.2 (C_pA), 128.7 (C_oC), 128.9 (C_oB), 129.0 (C-5), 129.7 (C_mA), 130.0 (C_oA), 130.3 (C_mC), 130.7 (C_iB), 133.6 (C_iA), 134.2 (C-7), 138.0 (C_pC), 138.8 (C_pB), 151.6 (C-3), 163.9 (C_iC), 187.4 (C-8) ppm. MS (70 eV) m/z (%): 418 (10, M⁺), 279 (100), 77 (38). Anal. Calcd for C₂₄H₁₆Cl₂N₂O: C, 68.75; H, 3.85; N, 6.68. Found: C, 68.79; H, 3.80; N, 6.65.

4.1.12. (E)-1-(4-Bromophenyl)-3-[3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl]prop-2-en-1-one (6d)

Yellow solid, 96% yield; mp: 192 °C. FTIR (KBr), ν (cm⁻¹): 1659 (C=O and C=N), 1597 (C=C); ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.42 (t, 1H, H_pA, *J* = 7.51 Hz), 7.59 (t, 2H, H_mA, *J* = 8.27 Hz), 7.62 (d, 2H, H_oC, *J* = 8.48 Hz), 7.68 (d, 1H, H-7, *J* = 15.52 Hz), 7.70 (d, 2H, H_oB, *J* = 8.69 Hz), 7.80 (d, 2H, H_mC, *J* = 8.48 Hz), 7.83 (d, 1H, H-6, *J* = 15.54 Hz), 7.94 (d, 2H, H_oA, *J* = 7.65 Hz), 8.02 (d, 2H, H_mB, *J* = 8.69 Hz), 9.41 (s, 1H, H-5) ppm. ¹³C NMR (100 MHz, DMSO-*d*₆) δ 117.8 (C-4), 118.7 (C_oA), 121.2 (C-6), 127.2 (C_pA), 127.3 (C_iB), 128.9 (C_oC), 129.0 (C-5), 129.7 (C_mA), 130.0 (C_mC), 130.2 (C_mB), 130.7 (C_iC), 131.8 (C_oB), 133.4 (C_pC), 134.3 (C-7), 136.5 (C_pB), 138.8 (C_iA), 151.6 (C-3), 187.6 (C-8) ppm. MS (70 eV) m/z (%): 462 (5, M⁺), 464 (9), 279 (100), 77 (44). Anal. Calcd for C₂₄H₁₆ClBrN₂O: C, 62.16; H, 3.48; N, 6.04. Found: C, 62.10; H, 3.52; N, 6.14.

4.1.13. (E)-3-[3-(4-Chlorophenyl)-1-phenyl-1H-pyrazol-4-yl]-1-phenyl-prop-2-en-1-one (6e)

Yellow solid, 78% yield; mp: 175 °C. FTIR (KBr), ν (cm⁻¹): 1662 (C=O and C=N), 1606 (C=C); ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.42 (t, 1H, H_pA, *J* = 7.44 Hz), 7.58 (t, 2H, H_mA, *J* = 8.69 Hz), 7.60 (t, 1H, H_pC, *J* = 7.03 Hz), 7.61 (d, 2H, H_mB, *J* = 7.65 Hz), 7.61 (d, 2H, H_mC, *J* = 7.42 Hz), 7.63 (d, 2H, H_oB, *J* = 7.60 Hz), 7.69 (d, 1H, H-7, *J* = 15.71 Hz), 7.71 (d, 2H, H_oA, *J* = 8.48 Hz), 7.81 (d, 1H, H-6, *J* = 15.48 Hz), 8.10 (d, 2H, H_oC, *J* = 7.75 Hz), 9.43 (s, 1H, H-5) ppm. ¹³C NMR (100 MHz, DMSO-*d*₆) δ 117.8 (C-4), 118.7 (C-6), 121.7 (C_mB), 127.2 (C_pA), 127.3 (C_iB), 128.2 (C_oC), 128.7 (C_mC), 128.9 (C-5), 129.7 (C_pC), 129.8 (C_mA), 130.0 (C_oA), 130.8 (C_oB), 133.6 (C_pB), 133.8 (C-7), 137.6 (C_iC), 138.9 (C_iA), 151.6 (C-3), 188.7 (C-8) ppm. MS (70 eV) m/z (%): 384 (24, M⁺), 279 (100), 77 (95). Anal. Calcd for C₂₄H₁₇ClN₂O: C, 74.90; H, 4.45; N, 7.28. Found: C, 74.94; H, 4.40; N, 7.32.

4.1.14. (E)-3-[3-(4-Chlorophenyl)-1-phenyl-1H-pyrazol-4-yl]-1-(4-methylphenyl)-prop-2-en-1-one (6f)

Yellow solid, 76% yield; mp: 176 °C. FTIR (KBr), ν (cm⁻¹): 1660 (C=O and C=N), 1595 (C=C); ¹H NMR (400 MHz, DMSO-*d*₆) δ 2.41 (s, 3H, H–CH₃), 7.39 (d, 2H, H_mC, *J* = 8.30 Hz), 7.42 (t, 1H, H_pA, *J* = 8.04 Hz), 7.60 (t, 2H, H_mA, *J* = 8.48 Hz), 7.63 (d, 2H, H_oB, *J* = 7.64 Hz), 7.66 (d, 1H, H-7, *J* = 15.93 Hz), 7.70 (d, 2H, H_oA, *J* = 8.68 Hz), 7.87 (d, 1H, H-6, *J* = 15.51 Hz), 7.85 (d, 2H, H_mB, *J* = 7.68 Hz), 8.01 (d, 2H, H_oC, *J* = 8.27 Hz), 9.42 (s, 1H, H-5) ppm. ¹³C NMR (100 MHz, DMSO-*d*₆) δ 21.1 (C–CH₃), 117.8 (C-4), 118.7 (C-6), 118.7 (C_mC), 121.7 (C_mB), 127.2 (C_pA), 128.9 (C_oB), 129.1 (C-5), 129.7 (C_mA), 130.0 (C_oA), 130.4 (C_oC), 130.8 (C_iB), 130.9 (C_pC), 133.3 (C-7), 133.5 (C_pB), 138.9 (C_iA), 143.5 (C_iC), 151.5 (C-3), 188.0 (C-8) ppm. MS (70 eV) m/z (%): 398 (4, M⁺), 279 (100), 119 (40), 77 (39). Anal. Calcd for C₂₅H₁₉ClN₂O: C, 75.28; H, 4.80; N, 7.02. Found: C, 75.30; H, 4.84; N, 7.12.

4.1.15. (E)-3-[3-(4-Chlorophenyl)-1-phenyl-1H-pyrazol-4-yl]-1-(4-methoxyphenyl)-prop-2-en-1-one (6g)

Yellow solid, 79% yield; mp: 167 °C. FTIR (KBr), ν (cm⁻¹): 1659 (C=O and C=N), 1597 (C=C), 1219 (O–CH₃); ¹H NMR (DMSO-*d*₆) δ 3.88 (s, 3H, H–OCH₃), 7.11 (d, 2H, H_mC, *J* = 8.89 Hz), 7.42 (t, 1H, H_pA,

$J = 7.45$ Hz), 7.60 (t, 2H, H_{m-A} , $J = 8.27$ Hz), 7.62 (d, 2H, H_o-B , $J = 7.76$ Hz), 7.65 (d, 1H, H-7, $J = 15.51$ Hz), 7.71 (d, 2H, H_o-A , $J = 8.48$ Hz), 7.87 (d, 1H, H-6, $J = 15.51$ Hz), 7.95 (d, 2H, H_m-B , $J = 8.47$ Hz), 8.10 (d, 2H, H_o-C , $J = 8.89$ Hz), 9.40 (s, 1H, H-5) ppm. ^{13}C NMR (100 MHz, DMSO- d_6) δ 55.5 (C-OCH $_3$), 114.0 (C_m-C), 117.9 (C-4), 118.7 (C-6), 121.7 (C_m-B), 127.2 (C_p-A), 128.8 (C_o-B), 128.9 (C-5), 129.6 (C_m-A), 130.0 (C_o-A), 130.4 (C_i-C), 130.5 (C_o-C), 130.8 (C_i-B), 132.8 (C-7), 133.5 (C_p-B), 138.9 (C_i-A), 151.4 (C-3), 163.1 (C_p-C), 186.8 (C-8) ppm. MS (70 eV) m/z (%): 414 (20, M $^+$), 279 (100), 77 (49). Anal. Calcd for $C_{25}H_{19}ClN_2O_2$: C, 72.37; H, 4.62; N, 6.75. Found: C, 72.41; H, 4.68; N, 6.70.

4.1.16. (E)-3-[3-(4-Chlorophenyl)-1-phenyl-1H-pyrazol-4-yl]-1-(3,4-methylenedioxyphenyl)-prop-2-en-1-one (6h)

Yellow solid, 82% yield; mp: 152 °C. FTIR (KBr), ν (cm $^{-1}$): 1657 (C=O and C=N), 1589 (C=C), 1258 and 1094 (O-CH $_2$ -O); ^1H NMR (400 MHz, DMSO- d_6) δ 6.17 (s, 2H, H-CH $_2$), 7.11 (d, 2H, H_m-C , $J = 8.27$ Hz), 7.42 (t, 1H, H_p-A , $J = 7.24$ Hz), 7.59 (t, 2H, H_m-A , $J = 7.65$ Hz), 7.61 (s, 1H, H_o-C), 7.63 (d, 2H, H_o-B , $J = 7.86$ Hz), 7.64 (d, 1H, H-7, $J = 15.30$ Hz), 7.70 (d, 2H, H_o-A , $J = 8.68$ Hz), 7.78 (d, 2H, H_o-C , $J = 8.27$ Hz), 7.84 (d, 1H, H-6, $J = 15.46$ Hz), 7.94 (d, 2H, H_m-B , $J = 7.86$ Hz), 9.39 (s, 1H, H-5) ppm. ^{13}C NMR (100 MHz, DMSO- d_6) δ 102.1 (C-CH $_2$), 108.1 (C_m-C), 117.9 (C-4), 118.7 (C_m-B), 121.6 (C-6), 124.6 (C_o-C), 128.8 (C-5), 128.9 (C_p-B), 129.2 (C_p-A), 129.4 (C_o-C), 129.7 (C_m-A), 130.0 (C_o-A), 130.8 (C_i-B), 132.3 (C_p-B), 133.0 (C-7), 133.5 (C_i-A), 138.9 (C_m-C), 138.9 (C_p-C), 148.0 (C_i-C), 151.5 (C-3), 186.4 (C-8) ppm. MS (70 eV) m/z (%): 428 (11, M $^+$), 279 (39), 149 (100), 77 (41). Anal. Calcd for $C_{25}H_{17}ClN_2O_3$: C, 70.01; H, 4.00; N, 6.53. Found: C, 70.11; H, 3.96; N, 6.60.

4.2. General procedure for synthesis of pyrazoles 7a–h

A mixture of chalcone **5a–h** (1.0 mmol), hydrazine hydrate (1.3 mmol) and DMF (0.2 mL) was placed into an open Pyrex-glass vessel and subjected to microwave irradiation with magnetic stirring for 5 min and with a maximum power of 300 W. Reaction progress was monitored by TLC and the precipitate formed was filtered off and recrystallized from ethanol, affording compounds **7a–h**. The *N*-acetyl derivatives **8/9a–h** were obtained from chalcones **5/6a–h** following the same procedure and using AcOH instead of DMF.

4.2.1. 3-(4-Nitrophenyl)-4-[3-(4-nitrophenyl)-4,5-dihydro-1H-pyrazol-5-yl]-1-phenyl-1H-pyrazole (7a)

Yellow solid, 94% yield; mp: 242 °C. FTIR (KBr), ν (cm $^{-1}$): 3300 (NH), 1675 (C=N), 1595 (C=C, Ar), 1506 and 1345 (NO $_2$). ^1H NMR (400 MHz, DMSO- d_6) δ 3.07 (dd, 1H, H-4a', $J_{4a'-4b'} = 16.54$ Hz, $J_{4a'-5'} = 10.54$ Hz), 3.63 (dd, 1H, H-4b', $J_{4b'-4a'} = 16.34$ Hz, $J_{4b'-5'} = 11.37$ Hz), 5.21 (t, 1H, H-5', $J_{5'-4a'} = 10.96$ Hz, $J_{5'-4b'} = 11.40$ Hz), 7.45 (t, 1H, H_p-A , $J = 7.45$ Hz), 7.51 (t, 2H, H_m-A , $J = 8.47$ Hz), 7.84 (d, 2H, H_o-A , $J = 7.86$ Hz), 7.93 (d, 2H, H_o-C , $J = 8.89$ Hz), 8.07 (d, 2H, H_o-B , $J = 8.69$ Hz), 8.24 (d, 2H, H_m-B , $J = 8.69$ Hz), 8.33 (d, 2H, H_m-C , $J = 8.87$ Hz), 8.68 (s, 1H, H-5). ^{13}C NMR (100 MHz, DMSO- d_6) δ 39.5 (C-4'), 55.6 (C-5'), 118.4 (C_o-A), 121.4 (C_m-C), 123.0 (C_m-B), 124.0 (C-4), 124.8 (C_o-B), 125.0 (C_o-C), 126.8 (C_p-A), 127.5 (C-5), 129.6 (C_m-A), 139.1 (C_i-A), 139.4 (C_i-B), 139.6 (C_i-C), 146.3 (C_p-B), 146.9 (C_p-C), 147.9 (C-3), 148.8 (C-3'). MS (70 eV) m/z (%): 454 (100, M $^+$), 426 (13), 345 (10), 77 (21). Anal. Calcd for $C_{24}H_{18}N_6O_4$: C, 63.43; H, 3.99; N, 18.49. Found: C, 63.50; H, 3.93; N, 18.52.

4.2.2. 4-[3-(4-Fluorophenyl)-4,5-dihydro-1H-pyrazol-5-yl]-3-(4-nitrophenyl)-1-phenyl-1H-pyrazole (7b)

Yellow solid, 89% yield; mp: 217 °C. FTIR (KBr), ν (cm $^{-1}$): 3289 (NH), 1679 (C=N), 1590 (C=C, Ar), 1505 and 1346 (NO $_2$). ^1H NMR (400 MHz, DMSO- d_6) δ 2.99 (dd, 1H, H-4a', $J_{4a'-4b'} = 16.29$ Hz,

$J_{4a'-5'} = 10.13$ Hz), 3.49 (dd, 1H, H-4b', $J_{4b'-4a'} = 16.36$ Hz, $J_{4b'-5'} = 10.75$ Hz), 5.13 (t, 1H, H-5', $J_{5'-4a'} = 10.44$ Hz, $J_{5'-4b'} = 11.00$ Hz), 7.13 (m, 1H, H_p-C), 7.19 (s, 1H, NH), 7.33 (t, 2H, H_p-A , $J = 7.65$ Hz), 7.50 (t, 2H, H_m-A , $J = 7.26$ Hz), 7.65 (m, 2H, H_m-C), 7.86 (d, 2H, H_o-A , $J = 7.65$ Hz), 8.04 (d, 2H, H_o-B , $J = 8.89$ Hz), 8.26 (d, 2H, H_m-B , $J = 8.69$ Hz), 8.45 (s, 1H, H-5). ^{13}C NMR (100 MHz, DMSO- d_6) δ 39.7 (C-4'), 54.5 (C-5'), 114.5 (C_o-C), 118.2 (C_o-A), 122.8 (C_m-B), 123.7 (C-4), 126.0 (C_p-A), 126.9 (C_m-C), 127.3 (C-5), 128.2 (C_o-B), 128.8 (C_m-A), 138.9 (C_i-A), 139.1 (C_i-B), 146.0 (C_p-B), 147.1 (C_p-C), 148.2 (C-3), 148.7 (C_i-C), 152.8 (C-3'). MS (70 eV) m/z (%): 427 (100, M $^+$), 305 (6), 345 (10), 77 (12). Anal. Calcd for $C_{24}H_{18}FN_5O_2$: C, 67.44; H, 4.24; N, 16.38. Found: C, 67.48; H, 4.19; N, 16.30.

4.2.3. 4-[3-(4-Chlorophenyl)-4,5-dihydro-1H-pyrazol-5-yl]-3-(4-nitrophenyl)-1-phenyl-1H-pyrazole (7c)

Yellow solid, 92% yield; mp: 224 °C. FTIR (KBr), ν (cm $^{-1}$): 3309 (NH), 1669 (C=N), 1596 (C=C, Ar), 1501 and 1340 (NO $_2$). ^1H NMR (400 MHz, DMSO- d_6) δ 2.99 (dd, 1H, H-4a', $J_{4a'-4b'} = 16.29$ Hz, $J_{4a'-5'} = 10.75$ Hz), 3.55 (dd, 1H, H-4b', $J_{4b'-4a'} = 16.36$ Hz, $J_{4b'-5'} = 10.75$ Hz), 5.11 (t, 1H, H-5', $J_{5'-4a'} = 10.81$ Hz, $J_{5'-4b'} = 11.15$ Hz), 7.35 (t, 1H, H_p-A , $J = 7.44$ Hz), 7.44 (d, 2H, H_o-C , $J = 8.47$ Hz), 7.53 (t, 2H, H_m-A , $J = 7.44$ Hz), 7.65 (d, 2H, H_m-C , $J = 8.48$ Hz), 7.96 (d, 2H, H_o-A , $J = 7.65$ Hz), 8.08 (d, 2H, H_o-B , $J = 11.30$ Hz), 8.32 (d, 2H, H_m-B , $J = 11.37$ Hz), 8.65 (s, 1H, H-5). ^{13}C NMR (100 MHz, DMSO- d_6) δ 39.8 (C-4'), 55.2 (C-5'), 118.4 (C_o-A), 123.0 (C_m-B), 124.0 (C-4), 124.1 (C_o-C), 124.9 (C_o-B), 126.7 (C_p-A), 127.7 (C-5), 128.7 (C_m-C), 129.6 (C_m-A), 130.0 (C_p-C), 132.0 (C_i-C), 139.2 (C_i-A), 139.4 (C_i-B), 146.7 (C_p-B), 147.9 (C-3), 148.3 (C-3'). MS (70 eV) m/z (%): 443 (100, M $^+$), 305 (7), 77 (19). Anal. Calcd for $C_{24}H_{18}ClN_5O_2$: C, 64.94; H, 4.09; N, 15.78. Found: C, 64.90; H, 4.19; N, 15.88.

4.2.4. 4-[3-(4-Bromophenyl)-4,5-dihydro-1H-pyrazol-5-yl]-3-(4-nitrophenyl)-1-phenyl-1H-pyrazole (7d)

Yellow solid, 96% yield; mp: 231 °C. FTIR (KBr), ν (cm $^{-1}$): 3296 (NH), 1676 (C=N), 1595 (C=C, Ar), 1502 and 1341 (NO $_2$). ^1H NMR (400 MHz, DMSO- d_6) δ 2.96 (dd, 1H, H-4a', $J_{4a'-4b'} = 16.13$ Hz, $J_{4a'-5'} = 10.13$ Hz), 3.52 (dd, 1H, H-4b', $J_{4b'-4a'} = 16.23$ Hz, $J_{4b'-5'} = 10.75$ Hz), 5.08 (t, 1H, H-5', $J_{5'-4a'} = 10.54$ Hz, $J_{5'-4b'} = 11.36$ Hz), 7.33 (t, 1H, H_p-A , $J = 8.48$ Hz), 7.51 (t, 2H, H_m-A , $J = 7.44$ Hz), 7.55 (s, 2H, H_o-C), 7.58 (s, 2H, H_m-C), 7.80 (d, 2H, H_o-A , $J = 7.65$ Hz), 8.05 (d, 2H, H_o-B , $J = 9.10$ Hz), 8.30 (d, 2H, H_m-B , $J = 8.89$ Hz), 8.63 (s, 1H, H-5). ^{13}C NMR (100 MHz, DMSO- d_6) δ 40.1 (C-4'), 55.7 (C-5'), 119.0 (C_o-A), 121.7 (C_i-C), 124.3 (C_m-B), 124.5 (C-4), 127.2 (C_p-A), 127.9 (C_o-C), 129.2 (C_o-B), 129.9 (C_m-A), 130.1 (C-5), 131.9 (C_m-C), 139.6 (C_i-A), 139.9 (C_i-B), 147.2 (C_p-B), 148.4 (C-3), 149.0 (C-3'), 149.2 (C_p-C). MS (70 eV) m/z (%): 487 (100, M $^+$), 33 (31), 77 (42). Anal. Calcd for $C_{24}H_{18}BrN_5O_2$: C, 59.03; H, 3.72; N, 14.34. Found: C, 59.12; H, 3.69; N, 14.44.

4.2.5. 3-(4-Nitrophenyl)-1-phenyl-4-[3-phenyl-4,5-dihydro-1H-pyrazol-5-yl]-1H-pyrazole (7e)

Yellow solid, 90% yield; mp: 207 °C. FTIR (KBr), ν (cm $^{-1}$): 3310 (NH), 1663 (C=N), 1595 (C=C, Ar), 1503 and 1337 (NO $_2$). ^1H NMR (400 MHz, DMSO- d_6) δ 3.00 (dd, 1H, H-4a', $J_{4a'-4b'} = 16.20$ Hz, $J_{4a'-5'} = 10.45$ Hz), 3.55 (dd, 1H, H-4b', $J_{4b'-4a'} = 16.35$ Hz, $J_{4b'-5'} = 11.20$ Hz), 5.11 (t, 1H, H-5', $J_{5'-4a'} = 10.46$ Hz, $J_{5'-4b'} = 11.33$ Hz), 7.32 (t, 1H, H_p-A , $J = 7.49$ Hz), 7.49 (d, 2H, H_m-C , $J = 8.15$ Hz), 7.51 (t, 2H, H_m-A , $J = 7.03$ Hz), 7.63 (d, 2H, H_o-C , $J = 7.44$ Hz), 7.88 (d, 2H, H_o-A , $J = 7.65$ Hz), 8.06 (d, 2H, H_o-B , $J = 8.49$ Hz), 8.28 (d, 2H, H_m-B , $J = 8.69$ Hz), 8.54 (s, 1H, H-5). ^{13}C NMR (100 MHz, DMSO- d_6) δ 39.6 (C-4'), 54.5 (C-5'), 118.2 (C_o-A), 120.0 (C_o-C), 122.8 (C_m-B), 123.8 (C-4), 124.9 (C_o-B), 126.0 (C_p-A), 127.3 (C_p-C), 127.4 (C-5), 128.2 (C_m-C), 128.9 (C_m-A), 132.8 (C_i-C), 138.9 (C_i-A), 139.2 (C_i-B), 146.6 (C_p-B), 147.6 (C-3), 148.9 (C-3'). MS (70 eV) m/z (%): 409 (100, M $^+$), 244 (19), 118 (17), 77 (15). Anal. Calcd for

C₂₄H₁₉N₅O₂: C, 70.40; H, 4.68; N, 17.10. Found: C, 70.46; H, 4.60; N, 17.20.

4.2.6. 3-(4-Nitrophenyl)-1-phenyl-4-[3-(4-methylphenyl)-4,5-dihydro-1H-pyrazol-5-yl]-1H-pyrazole (7f)

Yellow solid, 91% yield; mp: 249 °C, FTIR (KBr), ν (cm⁻¹): 3300 (NH), 1675 (C=N), 1592 (C=C, Ar), 1506 and 1345 (NO₂). ¹H NMR (400 MHz, DMSO-*d*₆) δ 2.32 (s, 3H, H-CH₃), 2.98 (m, 1H, H-4a'), 3.48 (m, 1H, H-4b'), 5.12 (m, 1H, H-5'), 7.17 (d, 2H, H_o-C, *J* = 8.07 Hz), 7.34 (t, 1H, H_p-A, *J* = 7.50 Hz), 7.51 (t, 2H, H_m-A, *J* = 7.37 Hz), 7.51 (d, 2H, H_m-C, *J* = 8.07 Hz), 7.87 (d, 2H, H_o-A, *J* = 8.27 Hz), 8.06 (d, 2H, H_o-B, *J* = 8.68 Hz), 8.27 (d, 2H, H_m-B, *J* = 8.68 Hz), 8.46 (s, 1H, H-5). RMN ¹³C (100 MHz, DMSO-*d*₆) δ 19.9 (C-CH₃), 39.7 (C-4'), 54.4 (C-5'), 118.2 (C_o-A), 122.9 (C_o-C), 123.8 (C_m-B), 124.8 (C-4), 124.9 (C_o-B), 126.5 (C_p-A), 127.2 (C-5), 128.4 (C_i-C), 129.0 (C_p-C), 129.6 (C_m-A), 137.0 (C_m-C), 138.9 (C_i-A), 139.2 (C_i-B), 147.6 (C_p-B), 149.1 (C-3), 153.0 (C-3'). MS (70 eV) *m/z* (%): 423 (82, M⁺), 245 (21), 131 (61), 77 (100). Anal. Calcd for: C₂₅H₂₁N₅O₂: C, 70.91; H, 5.00; N, 16.54. Found: C, 70.98; H, 5.10; N, 16.52.

4.2.7. 4-[3-(4-Methoxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl]-3-(4-nitrophenyl)-1-phenyl-1H-pyrazole (7g)

Yellow solid, 93% yield; mp: 239 °C, FTIR (KBr), ν (cm⁻¹): 3300 (NH), 1679 (C=N), 1590 (C=C, Ar), 1504 and 1339 (NO₂). ¹H NMR (400 MHz, DMSO-*d*₆) δ 2.96 (dd, 1H, H-4a', *J*_{4a'-4b'} = 16.13 Hz, *J*_{4a'-5'} = 10.13 Hz), 3.45 (dd, 1H, H-4b', *J*_{4b'-4a'} = 16.23 Hz, *J*_{4b'-5'} = 10.75 Hz), 3.78 (s, 3H, H-OCH₃), 5.09 (t, 1H, H-5', *J*_{5'-4a'} = 10.54 Hz, *J*_{5'-4b'} = 11.36 Hz), 6.92 (d, 2H, H_m-C, *J* = 8.89 Hz), 7.32 (t, 1H, H_p-A, *J* = 8.48 Hz), 7.49 (t, 2H, H_m-A, *J* = 7.44 Hz), 7.56 (d, 2H, H_o-C, *J* = 8.69 Hz), 7.85 (d, 2H, H_o-A, *J* = 7.65 Hz), 8.04 (d, 2H, H_o-B, *J* = 9.10 Hz), 8.25 (d, 2H, H_m-B, *J* = 8.89 Hz), 8.43 (s, 1H, H-5) ppm. ¹³C NMR (100 MHz, DMSO-*d*₆) δ 40.0 (C-4'), 51.1 (C-5'), 53.5 (C-OCH₃), 113.9 (C_m-C), 118.4 (C_o-A), 123.8 (C_m-B), 124.1 (C_p-A), 124.2 (C-4), 125.8 (C_o-B), 126.7 (C-5), 128.9 (C_m-A), 130.6 (C_o-C), 139.2 (C_i-A), 139.5 (C_i-B), 147.3 (C_p-B), 149.8 (C-3), 153.2 (C-3'), 159.5 (C_p-C), 162.9 (C_i-C) ppm. MS (70 eV) *m/z* (%): 439 (100, M⁺), 133 (14), 77 (21). Anal. Calcd for C₂₅H₂₁N₅O₃: C, 68.33; H, 4.82; N, 15.94. Found: C, 68.28; H, 4.86; N, 15.90.

4.2.8. 4-[3-(3,4-Methylenedioxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl]-3-(4-nitrophenyl)-1-phenyl-1H-pyrazole (7h)

Yellow solid, 95% yield; mp: 210 °C, FTIR (KBr), ν (cm⁻¹): 3298 (NH), 1680 (C=N), 1598 (C=C, Ar), 1505 and 1345 (NO₂). ¹H NMR (400 MHz, DMSO-*d*₆) δ 2.94 (dd, 1H, H-4a', *J*_{4a'-4b'} = 16.33 Hz, *J*_{4a'-5'} = 10.17 Hz), 3.44 (dd, 1H, H-4b', *J*_{4b'-4a'} = 16.34 Hz, *J*_{4b'-5'} = 10.75 Hz), 5.09 (t, 1H, H-5', *J*_{5'-4a'} = 10.54 Hz, *J*_{5'-4b'} = 11.54 Hz), 5.97 (s, 2H, H-CH₂), 7.06 (d, 1H, H_m-C, *J* = 8.06 Hz), 7.19 (s, 1H, H_o-C), 7.33 (t, 1H, H_p-A, *J* = 7.85 Hz), 7.49 (t, 2H, H_m-A, *J* = 7.45 Hz), 7.84 (d, 1H, H_o-C, *J* = 8.07 Hz), 7.85 (d, 2H, H_o-A, *J* = 7.65 Hz), 8.03 (d, 2H, H_o-B, *J* = 8.69 Hz), 8.25 (d, 2H, H_m-B, *J* = 8.68 Hz), 8.43 (s, 1H, H-5). ¹³C NMR (100 MHz, DMSO-*d*₆) δ 39.9 (C-4'), 54.4 (C-5'), 100.4 (C-CH₂), 107.4 (C_m-C), 118.2 (C_o-A), 119.4 (C_o-C), 122.9 (C_m-B), 123.7 (C-4), 124.9 (C_m-C), 126.0 (C_p-A), 127.3 (C-5), 128.2 (C_o-B), 128.8 (C_m-A), 138.9 (C_i-A), 139.1 (C_i-B), 146.6 (C_p-B), 147.1 (C_i-C), 147.2 (C_p-C), 147.6 (C-3), 150.3 (C-3'). MS (70 eV) *m/z* (%): 453 (100, M⁺), 423 (10), 406 (9), 77 (22). Anal. Calcd for C₂₅H₁₉N₅O₄: C, 66.22; H, 4.22; N, 15.44. Found: C, 66.28; H, 4.12; N, 15.51.

4.2.9. 1-Acetyl-3-(4-nitrophenyl)-5-[3-(4-nitrophenyl)-1-phenyl-1H-pyrazol-4-yl]-4,5-dihydro-1H-pyrazole (8a)

Yellow solid, 94% yield; mp: 260 °C, FTIR (KBr), ν (cm⁻¹): 1660 (C=O, C=N), 1596 (C=C, Ar), 1502 and 1340 (NO₂). ¹H NMR (400 MHz, DMSO-*d*₆) δ 2.30 (s, 3H, H-COCH₃), 3.06 (dd, 1H, H-4a', *J*_{4a'-4b'} = 17.15 Hz, *J*_{4a'-5'} = 5.62 Hz), 3.56 (dd, 1H, H-4b',

*J*_{4b'-4a'} = 17.32 Hz, *J*_{4b'-5'} = 11.96 Hz), 5.24 (t, 1H, H-5', *J*_{5'-4a'} = 5.40 Hz, *J*_{5'-4b'} = 12.00 Hz), 7.32 (t, 2H, H_p-A, *J* = 7.04 Hz), 7.47 (t, 2H, H_m-A, *J* = 7.48 Hz), 7.82 (d, 2H, H_o-C, *J* = 8.89 Hz), 7.87 (d, 2H, H_o-A, *J* = 8.66 Hz), 8.03 (d, 2H, H_o-B, *J* = 8.74 Hz), 8.17 (d, 2H, H_m-B, *J* = 8.65 Hz), 8.30 (d, 2H, H_m-C, *J* = 8.70 Hz), 8.47 (s, 1H, H-5) ppm. ¹³C NMR (100 MHz, DMSO-*d*₆) δ 20.9 (C-COCH₃), 41.3 (C-4'), 52.0 (C-5'), 118.2 (C_o-A), 122.8 (C_m-C), 122.9 (C_m-B), 124.0 (C-4), 126.1 (C_p-A), 127.0 (C-5), 128.6 (C_o-C), 128.8 (C_o-B), 128.8 (C_m-A), 138.8 (C_i-A), 139.1 (C_i-B), 139.4 (C_i-C), 146.0 (C_p-B), 146.3 (C_p-C), 148.0 (C-3), 152.3 (C-3'), 165.9 (C=O) ppm. MS (70 eV) *m/z* (%): 454 (100, M⁺), 426 (11), 407 (11), 77 (25). Anal. Calcd for C₂₆H₂₀N₆O₅: C, 62.90; H, 4.06; N, 16.93. Found: C, 62.93; H, 4.03; N, 16.90.

4.2.10. 1-Acetyl-3-(4-fluorophenyl)-5-[3-(4-nitrophenyl)-1-phenyl-1H-pyrazol-4-yl]-4,5-dihydro-1H-pyrazole (8b)

Yellow solid, 90% yield; mp: 304 °C, FTIR (KBr), ν (cm⁻¹): 1659 (C=O, C=N), 1596 (C=C, Ar), 1508 and 1347 (NO₂). ¹H NMR (400 MHz, DMSO-*d*₆) δ 2.30 (s, 3H, H-COCH₃), 3.23 (dd, 1H, H-4a', *J*_{4a'-4b'} = 17.78 Hz, *J*_{4a'-5'} = 5.58 Hz), 3.70 (dd, 1H, H-4b', *J*_{4b'-4a'} = 17.79 Hz, *J*_{4b'-5'} = 11.99 Hz), 5.24 (t, 1H, H-5', *J*_{5'-4a'} = 5.38 Hz, *J*_{5'-4b'} = 11.58 Hz), 7.22 (m, 2H, H_o-C), 7.33 (t, 2H, H_p-A, *J* = 7.24 Hz), 7.49 (t, 2H, H_m-A, *J* = 7.03 Hz), 7.79 (m, 2H, H_m-C), 7.85 (d, 2H, H_o-A, *J* = 8.48 Hz), 8.04 (d, 2H, H_o-B, *J* = 8.69 Hz), 8.26 (d, 2H, H_m-B, *J* = 8.68 Hz), 8.29 (s, 1H, H-5). ¹³C NMR (100 MHz, DMSO-*d*₆) δ 20.9 (C-COCH₃), 41.6 (C-4'), 51.5 (C-5'), 114.8 (C_o-C), 118.2 (C_o-A), 122.7 (C_m-B), 123.4 (C-4), 126.0 (C_p-A), 126.7 (C-5), 128.2 (C_m-C), 128.5 (C_o-B), 128.7 (C_m-A), 138.8 (C_i-A), 139.1 (C_i-B), 146.7 (C_p-B), 147.1 (C-3), 152.3 (C-3'), 161.5 (C_p-C), 163.9 (C_i-C), 167.1 (C=O). MS (70 eV) *m/z* (%): 427 (100, M⁺), 244 (21), 137 (21), 77 (28). Anal. Calcd for C₂₆H₂₀FN₅O₃: C, 66.52; H, 4.29; N, 14.92. Found: C, 66.56; H, 4.26; N, 14.88.

4.2.11. 1-Acetyl-3-(4-chlorophenyl)-5-[3-(4-nitrophenyl)-1-phenyl-1H-pyrazol-4-yl]-4,5-dihydro-1H-pyrazole (8c)

White solid, 91% yield; mp: 311 °C, FTIR (KBr), ν (cm⁻¹): 1659 (C=O, C=N), 1593 (C=C, Ar), 1508 and 1347 (NO₂). ¹H NMR (400 MHz, DMSO-*d*₆) δ 2.94 (dd, 1H, H-4a', *J*_{4a'-4b'} = 16.15 Hz, *J*_{4a'-5'} = 5.45 Hz), 2.98 (s, 3H, H-COCH₃), 3.50 (dd, 1H, H-4b', *J*_{4b'-4a'} = 16.80 Hz, *J*_{4b'-5'} = 10.80 Hz), 5.15 (t, 1H, H-5', *J*_{5'-4a'} = 5.49 Hz, *J*_{5'-4b'} = 11.54 Hz), 7.33 (t, 1H, H_p-A, *J* = 7.48 Hz), 7.52 (d, 2H, H_o-C, *J* = 8.40 Hz), 7.55 (t, 2H, H_m-A, *J* = 7.48 Hz), 7.70 (d, 2H, H_m-C, *J* = 8.45 Hz), 7.97 (d, 2H, H_o-A, *J* = 7.65 Hz), 8.05 (d, 2H, H_o-B, *J* = 8.69 Hz), 8.30 (d, 2H, H_m-B, *J* = 8.60 Hz), 8.60 (s, 1H, H-5). ¹³C NMR (100 MHz, DMSO-*d*₆) δ 20.9 (C-COCH₃), 39.9 (C-4'), 55.4 (C-5'), 118.2 (C_o-A), 123.4 (C_m-B), 123.9 (C-4), 124.1 (C_o-C), 125.3 (C_o-B), 126.8 (C_p-A), 127.5 (C-5), 128.6 (C_m-C), 129.6 (C_p-C), 129.8 (C_m-A), 132.8 (C_i-C), 139.0 (C_i-A), 139.4 (C_i-B), 146.8 (C_p-B), 147.8 (C-3), 149.3 (C-3'), 166.8 (C=O). MS (70 eV) *m/z* (%): 485 (100, M⁺), 340 (22), 77 (41). Anal. Calcd for C₂₆H₂₀ClN₅O₃: C, 64.27; H, 4.15; N, 14.41. Found: C, 64.24; H, 4.14; N, 14.44.

4.2.12. 1-Acetyl-3-(4-bromophenyl)-5-[3-(4-nitrophenyl)-1-phenyl-1H-pyrazol-4-yl]-4,5-dihydro-1H-pyrazole (8d)

White solid, 96% yield; mp: 318 °C, FTIR (KBr), ν (cm⁻¹): 1658 (C=O, C=N), 1591 (C=C, Ar), 1500 and 1339 (NO₂). ¹H NMR (400 MHz, DMSO-*d*₆) δ 2.98 (s, 3H, H-COCH₃), 3.21 (dd, 1H, H-4a', *J*_{4a'-4b'} = 17.79 Hz, *J*_{4a'-5'} = 5.52 Hz), 3.88 (dd, 1H, H-4b', *J*_{4b'-4a'} = 17.99 Hz, *J*_{4b'-5'} = 11.99 Hz), 5.76 (t, 1H, H-5', *J*_{5'-4a'} = 5.39 Hz, *J*_{5'-4b'} = 13.18 Hz), 7.31 (t, 2H, H_p-A, *J* = 6.83 Hz), 7.47 (t, 2H, H_m-A, *J* = 7.24 Hz), 7.60 (d, 2H, H_o-C, *J* = 8.48 Hz), 7.66 (d, 2H, H_m-C, *J* = 8.68 Hz), 7.83 (d, 2H, H_o-A, *J* = 8.07 Hz), 8.02 (d, 2H, H_o-B, *J* = 8.89 Hz), 8.24 (d, 2H, H_m-B, *J* = 8.68 Hz), 8.45 (s, 1H, H-5). ¹³C NMR (100 MHz, DMSO-*d*₆) δ 20.9 (C-COCH₃), 41.4 (C-4'), 51.4 (C-5'), 118.2 (C_o-A), 122.7 (C_m-B), 122.9 (C_i-C), 123.4 (C-4), 126.0 (C_p-A), 126.5 (C-5), 128.7 (C_o-B), 128.9 (C_m-A), 130.0 (C_p-C),

130.9 (C_o-C), 133.3 (C_m-C), 138.8 (C_i-A), 139.1 (C_i-B), 146.3 (C_p-B), 148.6 (C-3), 152.3 (C-3'), 174.7 (C=O). MS (70 eV) *m/z* (%): 487 (100, M⁺), 228 (24), 182 (30), 77 (53). Anal. Calcd for C₂₆H₂₀BrN₅O₃: C, 58.88; H, 3.80; N, 13.20. Found: C, 58.80; H, 3.86; N, 13.24.

4.2.13. 1-Acetyl-5-[3-(4-nitrophenyl)-1-phenyl-1H-pyrazol-4-yl]-3-phenyl-4,5-dihydro-1H-pyrazole (8e)

White solid, 91% yield; mp: 291 °C, FTIR (KBr), ν (cm⁻¹): 1658 (C=O, C=N), 1594 (C=C, Ar), 1503 and 1339 (NO₂). ¹H NMR (400 MHz, DMSO-*d*₆) δ 2.29 (s, 3H, H-COCH₃), 3.00 (m, 1H, H-4a'), 3.89 (m, 1H, H-4b'), 5.13 (m, 1H, H-5'), 7.33 (t, 1H, H_p-A, *J* = 7.20 Hz), 7.40 (t, 1H, H_p-C, *J* = 7.56 Hz), 7.42 (d, 2H, H_m-C, *J* = 7.62 Hz), 7.45 (t, 2H, H_m-A, *J* = 7.44 Hz), 7.66 (d, 2H, H_o-C, *J* = 8.40 Hz), 7.84 (d, 2H, H_o-A, *J* = 8.31 Hz), 8.04 (d, 2H, H_o-B, *J* = 8.68 Hz), 8.25 (d, 2H, H_m-B, *J* = 8.69 Hz), 8.45 (s, 1H, H-5). ¹³C NMR (100 MHz, DMSO-*d*₆) δ 20.9 (C-COCH₃), 41.5 (C-4'), 51.4 (C-5'), 118.2 (C_o-A), 119.4 (C_o-C), 122.8 (C_m-B), 123.3 (C_m-C), 123.5 (C-4), 125.9 (C_p-C), 126.1 (C_p-A), 126.8 (C-5), 128.3 (C_m-A), 128.5 (C_o-B), 129.3 (C_i-C), 138.8 (C_i-A), 139.1 (C_i-B), 146.6 (C_p-B), 148.6 (C-3), 153.2 (C-3'), 166.9 (C=O). MS (70 eV) *m/z* (%): 442 (21, M⁺), 397 (100), 279 (46), 77 (32). Anal. Calcd for C₂₆H₂₁N₅O₃: C, 69.17; H, 4.69; N, 15.51. Found: C, 69.18; H, 4.67; N, 15.41.

4.2.14. 1-Acetyl-3-(4-methylphenyl)-5-[3-(4-nitrophenyl)-1-phenyl-1H-pyrazol-4-yl]-4,5-dihydro-1H-pyrazole (8f)

White solid, 90% yield; mp: 296 °C, FTIR (KBr), ν (cm⁻¹): 1658 (C=O, C=N), 1594 (C=C, Ar), 1505 and 1340 (NO₂). ¹H NMR (400 MHz, DMSO-*d*₆) δ 2.28 (s, 3H, H-COCH₃), 2.34 (s, 3H, H-CH₃), 3.19 (m, 1H, H-4a'), 3.86 (m, 1H, H-4b'), 5.76 (m, 1H, H-5'), 7.24 (d, 2H, H_o-C, *J* = 8.15 Hz), 7.32 (t, 2H, H_p-A, *J* = 7.23 Hz), 7.40 (d, 2H, H_m-C, *J* = 8.15 Hz), 7.46 (t, 2H, H_m-A, *J* = 7.56 Hz), 7.83 (d, 2H, H_o-A, *J* = 8.07 Hz), 8.03 (d, 2H, H_o-B, *J* = 8.69 Hz), 8.24 (d, 2H, H_m-B, *J* = 8.68 Hz), 8.25 (s, 1H, H-5). ¹³C NMR (100 MHz, DMSO-*d*₆) δ 20.1 (C-CH₃), 20.9 (C-COCH₃), 41.6 (C-4'), 51.3 (C-5'), 118.2 (C_o-A), 122.7 (C_m-B), 123.5 (C-4), 125.9 (C_o-C), 126.0 (C_p-A), 126.7 (C-5), 127.3 (C_m-C), 128.1 (C_i-C), 128.3 (C_p-C), 128.5 (C_m-A), 128.7 (C_o-B), 138.8 (C_i-A), 139.3 (C_i-B), 146.7 (C_p-B), 147.1 (C-3), 153.2 (C-3'), 167.1 (C=O). MS (70 eV) *m/z* (%): 465 (55, M⁺), 423 (100), 77 (33). Anal. Calcd for: C₂₇H₂₃N₅O₃: C, 69.66; H, 4.98; N, 15.04. Found: C, 69.76; H, 4.94; N, 15.14.

4.2.15. 1-Acetyl-3-(4-methoxyphenyl)-5-[3-(4-nitrophenyl)-1-phenyl-1H-pyrazol-4-yl]-4,5-dihydro-1H-pyrazole (8g)

White solid, 93% yield; mp: 293 °C, FTIR (KBr), ν (cm⁻¹): 1654 (C=O, C=N), 1598 (C=C, Ar), 1503 and 1338 (NO₂). ¹H NMR (400 MHz, DMSO-*d*₆) δ 2.27 (s, 3H, H-COCH₃), 3.28 (dd, 1H, H-4a', *J*_{4a'-4b'} = 17.71 Hz, *J*_{4a'-5'} = 5.50 Hz), 3.80 (s, 3H, H-OCH₃), 3.85 (dd, 1H, H-4b', *J*_{4b'-4a'} = 18.20 Hz, *J*_{4b'-5'} = 13.44 Hz), 5.73 (t, 1H, H-5', *J*_{5-4a'} = 5.48 Hz, *J*_{4b'-5'} = 13.02 Hz), 6.97 (d, 2H, H_m-C, *J* = 8.68 Hz), 7.31 (t, 2H, H_p-A, *J* = 7.86 Hz), 7.47 (t, 2H, H_m-A, *J* = 8.69 Hz), 7.66 (d, 2H, H_o-C, *J* = 8.89 Hz), 7.83 (d, 2H, H_o-A, *J* = 7.65 Hz), 8.03 (d, 2H, H_o-B, *J* = 8.98 Hz), 8.24 (d, 2H, H_m-B, *J* = 9.72 Hz), 8.25 (s, 1H, H-5). ¹³C NMR (100 MHz, DMSO-*d*₆) δ 20.9 (C-COCH₃), 41.6 (C-4'), 51.2 (C-5'), 54.8 (C-OCH₃), 113.8 (C_m-C), 118.2 (C_o-A), 122.7 (C_m-B), 123.5 (C_i-C), 123.6 (C-4), 125.9 (C_p-A), 126.8 (C-5), 127.5 (C_o-C), 128.5 (C_o-B), 128.7 (C_m-A), 138.8 (C_i-A), 139.1 (C_i-B), 146.7 (C_p-B), 147.1 (C-3), 152.6 (C-3'), 160.6 (C_p-C), 166.9 (C=O). MS (70 eV) *m/z* (%): 481 (53, M⁺), 439 (100), 133 (15), 77 (17). Anal. Calcd for C₂₇H₂₃N₅O₄: C, 67.35; H, 4.81; N, 14.54. Found: C, 67.30; H, 4.88; N, 14.56.

4.2.16. 1-Acetyl-3-(3,4-methylenedioxyphenyl)-5-[3-(4-nitrophenyl)-1-phenyl-1H-pyrazol-4-yl]-4,5-dihydro-1H-pyrazole (8h)

White solid, 90% yield; mp: 285 °C, FTIR (KBr), ν (cm⁻¹): 1655 (C=O, C=N), 1597 (C=C, Ar), 1508 and 1349 (NO₂). ¹H NMR

(400 MHz, DMSO-*d*₆) δ 2.26 (s, 3H, H-COCH₃), 3.15 (dd, 1H, H-4a', *J*_{4a'-4b'} = 17.78 Hz, *J*_{4a'-5'} = 5.38 Hz), 3.83 (dd, 1H, H-4b', *J*_{4b'-4a'} = 16.96 Hz, *J*_{4b'-5'} = 11.79 Hz), 5.73 (t, 1H, H-5', *J*_{5-4a'} = 5.48 Hz, *J*_{5-4b'} = 11.68 Hz), 6.02 (s, 2H, H-CH₂), 6.90 (d, 1H, H_o-C, *J* = 8.06 Hz), 7.19 (s, 1H, H_o-C), 7.27 (d, 1H, H_m-C, *J* = 8.06 Hz), 7.31 (t, 2H, H_p-A, *J* = 7.03 Hz), 7.47 (t, 2H, H_m-A, *J* = 7.24 Hz), 7.83 (d, 2H, H_o-A, *J* = 8.07 Hz), 8.04 (d, 2H, H_o-B, *J* = 8.40 Hz), 8.24 (d, 2H, H_m-B, *J* = 8.48 Hz), 8.25 (s, 1H, H-5) ppm. ¹³C NMR (100 MHz, DMSO-*d*₆) δ 21.9 (C-COCH₃), 41.7 (C-4'), 51.4 (C-5'), 100.8 (C-CH₂), 107.6 (C_m-C), 118.2 (C_o-A), 121.0 (C_o-C), 122.7 (C_m-B), 123.5 (C-4), 125.1 (C_m-C), 126.0 (C_p-A), 126.7 (C-5), 128.5 (C_o-B), 128.7 (C_m-A), 138.8 (C_i-A), 139.1 (C_i-B), 146.7 (C_p-B), 147.1 (C_i-C), 147.2 (C_p-C), 148.5 (C-3), 152.9 (C-3'), 166.5 (C=O) ppm. MS (70 eV) *m/z* (%): 496 (78, M⁺), 453 (100), 77 (18). Anal. Calcd for C₂₇H₂₁N₅O₅: C, 65.45; H, 4.27; N, 14.13. Found: C, 65.55; H, 4.29; N, 14.12.

4.2.17. 1-Acetyl-5-[3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl]-3-(4-nitrophenyl)-4,5-dihydro-1H-pyrazole (9a)

White solid, 93% yield; mp: 239 °C, FTIR (KBr), ν (cm⁻¹): 1676 (C=O, C=N), 1597 (C=C, Ar), 1506 and 1343 (NO₂). ¹H NMR (400 MHz, DMSO-*d*₆) δ 2.35 (s, 3H, H-COCH₃), 3.28 (dd, 1H, H-4a', *J*_{4a'-4b'} = 18.89 Hz, *J*_{4a'-5'} = 5.38 Hz), 3.95 (dd, 1H, H-4b', *J*_{4b'-4a'} = 17.99 Hz, *J*_{4b'-5'} = 11.99 Hz), 5.74 (t, 1H, H-5', *J*_{5-4a'} = 5.27 Hz, *J*_{4b'-5'} = 11.89 Hz), 7.30 (t, 2H, H_p-A, *J* = 7.44 Hz), 7.47 (t, 2H, H_m-A, *J* = 8.07 Hz), 7.53 (d, 2H, H_o-B, *J* = 8.27 Hz), 7.82 (d, 2H, H_m-B, *J* = 8.47 Hz), 7.88 (d, 2H, H_o-A, *J* = 8.09 Hz), 7.97 (d, 2H, H_o-C, *J* = 8.89 Hz), 8.30 (d, 2H, H_m-C, *J* = 8.90 Hz), 8.46 (s, 1H, H-5) ppm. ¹³C NMR (100 MHz, DMSO-*d*₆) δ 21.9 (C-COCH₃), 41.9 (C-4'), 52.3 (C-5'), 118.2 (C_o-A), 123.2 (C-4), 123.8 (C_m-C), 126.4 (C_p-A), 126.9 (C-5), 127.6 (C_o-C), 128.6 (C_o-B), 129.4 (C_m-A), 129.8 (C_m-B), 131.7 (C_p-B), 132.8 (C_i-B), 139.2 (C_i-A), 147.9 (C_p-C), 148.3 (C-3), 152.3 (C_i-C), 152.5 (C-3'), 168.0 (C=O) ppm. MS (70 eV) *m/z* (%): 485 (61, M⁺), 442 (100), 294 (81), 279 (65), 77 (42). Anal. Calcd for C₂₆H₂₀ClN₅O₃: C, 64.27; H, 4.15; N, 14.41. Found: C, 64.20; H, 4.22; N, 14.50.

4.2.18. 1-Acetyl-5-[3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl]-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole (9b)

White solid, 90% yield; mp: 234 °C, FTIR (KBr), ν (cm⁻¹): 1652 (C=O, C=N), 1600 (C=C, Ar). ¹H NMR (400 MHz, DMSO-*d*₆) δ 2.31 (s, 3H, H-COCH₃), 3.23 (dd, 1H, H-4a', *J*_{4a'-4b'} = 17.89 Hz, *J*_{4a'-5'} = 5.38 Hz), 3.89 (dd, 1H, H-4b', *J*_{4b'-4a'} = 17.79 Hz, *J*_{4b'-5'} = 12.00 Hz), 5.69 (t, 1H, H-5', *J*_{5-4a'} = 5.17 Hz, *J*_{4b'-5'} = 11.89 Hz), 7.28 (t, 2H, H_p-A, *J* = 7.44 Hz), 7.46 (t, 2H, H_m-A, *J* = 8.48 Hz), 7.53 (d, 2H, H_o-B, *J* = 8.68 Hz), 7.83 (m, 2H, H_o-C), 7.85 (d, 2H, H_m-B, *J* = 8.67 Hz), 7.89 (d, 2H, H_o-A, *J* = 8.68 Hz), 8.30 (m, 2H, H_m-C), 8.41 (s, 1H, H-5) ppm. ¹³C NMR (100 MHz, DMSO-*d*₆) δ 21.8 (C-COCH₃), 42.2 (C-4'), 51.6 (C-5'), 115.7 (C_m-C), 118.2 (C_o-A), 123.5 (C-4), 126.3 (C_p-A), 126.8 (C-5), 128.6 (C_o-B), 128.9 (C_o-C), 129.4 (C_m-A), 129.7 (C_m-B), 131.7 (C_p-B), 132.7 (C_i-B), 139.2 (C_i-A), 148.2 (C-3), 153.0 (C-3'), 161.9 (C_i-C), 164.4 (C_p-C), 167.6 (C=O) ppm. MS (70 eV) *m/z* (%): 458 (57, M⁺), 415 (100), 279 (42), 77 (33). Anal. Calcd for C₂₆H₂₀ClFN₄O₃: C, 68.05; H, 4.39; N, 12.21. Found: C, 68.15; H, 4.38; N, 12.31.

4.2.19. 1-Acetyl-3-(chlorophenyl)-5-[3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl]-4,5-dihydro-1H-pyrazole (9c)

White solid, 93% yield; mp: 261 °C, FTIR (KBr), ν (cm⁻¹): 1648 (C=O, C=N), 1601 (C=C, Ar). ¹H NMR (400 MHz, DMSO-*d*₆) δ 2.27 (s, 3H, H-COCH₃), 3.16 (dd, 1H, H-4a', *J*_{4a'-4b'} = 17.78 Hz, *J*_{4a'-5'} = 5.58 Hz), 3.82 (dd, 1H, H-4b', *J*_{4b'-4a'} = 17.78 Hz, *J*_{4b'-5'} = 11.78 Hz), 5.69 (t, 1H, H-5', *J*_{5-4a'} = 5.58 Hz, *J*_{4b'-5'} = 11.78 Hz), 7.27 (t, 2H, H_p-A, *J* = 7.44 Hz), 7.44 (m, 2H, H_m-A), 7.48 (d, 2H, H_o-B, *J* = 9.10 Hz), 7.81 (d, 2H, H_o-A, *J* = 8.69 Hz), 7.72 (d, 2H, H_m-C, *J* = 9.10 Hz), 7.74 (d, 2H, H_m-B, *J* = 8.89 Hz), 8.20 (s, 1H, H-5) ppm.

^{13}C NMR (100 MHz, DMSO- d_6) δ 20.9 (C-COCH $_3$), 41.4 (C-4'), 51.6 (C-5'), 118.0 (C $_o$ -A), 122.6 (C-4), 126.1 (C $_p$ -A), 126.6 (C-5), 127.7 (C $_o$ -C), 128.0 (C $_m$ -C), 128.6 (C $_o$ -B), 129.2 (C $_m$ -B), 129.3 (C $_p$ -C), 129.6 (C $_m$ -A), 129.8 (C $_i$ -C), 131.4 (C $_p$ -B), 132.3 (C $_i$ -B), 138.9 (C $_i$ -A), 148.1 (C-3), 152.1 (C-3'), 167.1 (C=O) ppm. MS (70 eV) m/z (%): 474 (63, M $^+$), 431 (100), 279 (62), 77 (95). Anal. Calcd for C $_{26}$ H $_{20}$ Cl $_2$ N $_4$ O: C, 65.69; H, 4.24; N, 11.79. Found: C, 65.71; H, 4.28; N, 11.84.

4.2.20. 1-Acetyl-3-(4-bromophenyl)-5-[3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl]-4,5-dihydro-1H-pyrazole (9d)

White solid, 96% yield; mp: 259 °C, FTIR (KBr), ν (cm $^{-1}$): 1646 (C=O, C=N), 1595 (C=C, Ar). ^1H NMR (400 MHz, DMSO- d_6) δ 2.27 (s, 3H, H-COCH $_3$), 3.16 (m, 1H, H-4a'), 3.82 (m, 1H, H-4b'), 5.69 (m, 1H, H-5'), 7.28 (t, 2H, H $_p$ -A, J = 6.85 Hz), 7.44 (d, 2H, H $_o$ -B, J = 8.48 Hz), 7.49 (t, 2H, H $_m$ -A, J = 8.48 Hz), 7.60 (d, 2H, H $_o$ -C, J = 10.54 Hz), 7.64 (d, 2H, H $_m$ -C, J = 8.70 Hz), 7.73 (d, 2H, H $_m$ -B, J = 8.70 Hz), 7.79 (d, 2H, H $_o$ -A, J = 8.07 Hz), 8.19 (s, 1H, H-5) ppm. ^{13}C NMR (100 MHz, DMSO- d_6) δ 20.9 (C-COCH $_3$), 41.3 (C-4'), 51.9 (C-5'), 118.0 (C $_o$ -A), 122.3 (C $_i$ -C), 122.7 (C-4), 125.6 (C $_p$ -A), 126.1 (C-5), 127.2 (C $_m$ -A), 127.7 (C $_m$ -C), 128.9 (C $_o$ -B), 129.2 (C $_m$ -B), 129.4 (C $_p$ -C), 130.9 (C $_o$ -C), 131.4 (C $_p$ -B), 132.3 (C $_i$ -B), 138.9 (C $_i$ -A), 148.1 (C-3), 152.2 (C-3'), 167.1 (C=O) ppm. MS (70 eV) m/z (%): 520 (64, M $^+$), 477 (100), 279 (64), 77 (37). Anal. Calcd for C $_{26}$ H $_{20}$ BrClN $_4$ O: C, 60.07; H, 3.88; N, 10.78. Found: C, 60.14; H, 3.92; N, 10.70.

4.2.21. 1-Acetyl-5-[3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl]-3-phenyl-4,5-dihydro-1H-pyrazole (9e)

White solid, 90% yield; mp: 249 °C, FTIR (KBr), ν (cm $^{-1}$): 1651 (C=O, C=N), 1597 (C=C, Ar). ^1H NMR (400 MHz, DMSO- d_6) δ 2.27 (s, 3H, H-COCH $_3$), 3.17 (m, 1H, H-4a'), 3.83 (m, 1H, H-4b'), 5.69 (m, 1H, H-5'), 7.27 (m, 2H, H $_p$ -A), 7.44 (m, 2H, H $_m$ -A), 7.44 (m, 1H, H $_p$ -C), 7.44 (m, 2H, H $_o$ -B), 7.64 (m, 2H, H $_m$ -C), 7.73 (m, 2H, H $_o$ -C), 7.73 (m, 2H, H $_m$ -B), 7.80 (d, 2H, H $_o$ -A, J = 8.15 Hz), 8.19 (s, 1H, H-5) ppm. ^{13}C NMR (100 MHz, DMSO- d_6) δ 20.9 (C-COCH $_3$), 41.5 (C-4'), 51.4 (C-5'), 118.0 (C $_o$ -A), 122.8 (C $_m$ -B), 122.9 (C-4), 125.6 (C $_o$ -C), 125.8 (C $_o$ -B), 126.1 (C $_p$ -A), 127.7 (C-5), 128.6 (C $_p$ -C), 129.2 (C $_m$ -C), 129.3 (C $_m$ -A), 130.9 (C $_i$ -C), 131.5 (C $_p$ -B), 132.3 (C $_i$ -B), 138.9 (C $_i$ -A), 148.1 (C-3), 153.1 (C-3'), 167.1 (C=O) ppm. MS (70 eV) m/z (%): 440 (59, M $^+$), 397 (100), 279 (64), 104 (39), 77 (52). Anal. Calcd for C $_{26}$ H $_{21}$ ClN $_4$ O: C, 70.82; H, 4.80; N, 12.71. Found: C, 70.80; H, 4.70; N, 12.64.

4.2.22. 1-Acetyl-5-[3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl]-3-(4-methylphenyl)-4,5-dihydro-1H-pyrazole (9f)

White solid, 93% yield; mp: 231 °C, FTIR (KBr), ν (cm $^{-1}$): 1661 (C=O, C=N), 1597 (C=C, Ar). ^1H NMR (400 MHz, DMSO- d_6) δ (s, 3H, H-COCH $_3$), 2.30 (s, 3H, H-CH $_3$), 3.22 (m, 1H, H-4a'), 3.80 (m, 1H, H-4b'), 5.82 (m, 1H, H-5'), 7.28 (d, 2H, H $_o$ -C, J = 8.22 Hz), 7.33 (t, 2H, H $_p$ -A, J = 7.33 Hz), 7.45 (d, 2H, H $_m$ -C, J = 8.21 Hz), 7.46 (t, 2H, H $_m$ -A, J = 7.56 Hz), 7.56 (d, 2H, H $_o$ -B, J = 7.69 Hz), 7.68 (d, 2H, H $_m$ -B, J = 7.67 Hz), 7.85 (d, 2H, H $_o$ -A, J = 8.17 Hz), 8.42 (s, 1H, H-5) ppm. ^{13}C NMR (100 MHz, DMSO- d_6) δ 20.9 (C-CH $_3$), 21.2 (C-COCH $_3$), 41.6 (C-4'), 52.3 (C-5'), 118.4 (C $_o$ -A), 122.8 (C $_m$ -B), 124.0 (C-4), 125.5 (C $_o$ -C), 126.0 (C $_p$ -A), 126.8 (C-5), 127.9 (C $_m$ -C), 128.0 (C $_i$ -C), 129.0 (C $_p$ -C), 129.5 (C $_m$ -A), 129.6 (C $_o$ -B), 139.1 (C $_i$ -A), 139.3 (C $_i$ -B), 147.2 (C-3), 147.6 (C $_p$ -B), 153.3 (C-3'), 168.1 (C=O) ppm. MS (70 eV) m/z (%): 454 (100, M $^+$), 364 (62), 77 (53). Anal. Calcd for C $_{27}$ H $_{23}$ ClN $_4$ O: C, 71.28; H, 5.10; N, 12.31. Found: C, 71.25; H, 5.15; N, 12.38.

4.2.23. 1-Acetyl-5-[3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl]-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole (9g)

White solid, 92% yield; mp: 219 °C, FTIR (KBr), ν (cm $^{-1}$): 1661 (C=O, C=N), 1596 (C=C, Ar). ^1H NMR (400 MHz, DMSO- d_6) δ 2.26

(s, 3H, H-COCH $_3$), 3.13 (m, 1H, H-4a'), 3.80 (m, 1H, H-4b'), 3.92 (s, 3H, H-OCH $_3$), 5.66 (m, 1H, H-5'), 6.98 (d, 2H, H $_m$ -C, J = 10.96 Hz), 7.23 (t, 2H, H $_p$ -A, J = 7.23 Hz), 7.43 (d, 2H, H $_o$ -C, J = 10.96 Hz), 7.50 (d, 2H, H $_o$ -B, J = 10.70 Hz), 7.64 (m, 2H, H $_m$ -A), 7.76 (d, 2H, H $_m$ -B, J = 10.75 Hz), 7.82 (d, 2H, H $_o$ -A, J = 6.89 Hz), 8.17 (s, 1H, H-5) ppm. ^{13}C NMR (100 MHz, DMSO- d_6) δ 20.9 (C-COCH $_3$), 41.6 (C-4'), 51.3 (C-5'), 55.0 (C-OCH $_3$), 113.7 (C $_m$ -C), 118.0 (C $_o$ -A), 122.9 (C $_p$ -C), 123.6 (C-4), 125.6 (C $_p$ -A), 126.0 (C-5), 127.5 (C $_o$ -C), 128.6 (C $_o$ -B), 129.2 (C $_m$ -B), 130.2 (C $_m$ -A), 131.5 (C $_p$ -B), 132.3 (C $_i$ -B), 138.9 (C $_i$ -A), 148.1 (C-3), 152.9 (C-3'), 160.6 (C $_i$ -C), 166.8 (C=O) ppm. MS (70 eV) m/z (%): 470 (100, M $^+$), 364 (52), 279 (60), 77 (80). Anal. Calcd for C $_{27}$ H $_{23}$ ClN $_4$ O $_2$: C, 68.86; H, 4.92; N, 11.90. Found: C, 68.80; H, 4.96; N, 11.90.

4.2.24. 1-Acetyl-3-(3,4-methylenedioxyphenyl)-5-[3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl]-4,5-dihydro-1H-pyrazole (9h)

White solid, 89% yield; mp: 225 °C, FTIR (KBr), ν (cm $^{-1}$): 1649 (C=O, C=N), 1599 (C=C, Ar). ^1H NMR (400 MHz, DMSO- d_6) δ 2.29 (s, 3H, H-COCH $_3$), 3.17 (m, 1H, H-4a'), 3.83 (m, 1H, H-4b'), 5.65 (m, 1H, H-5'), 6.09 (s, 2H, H-CH $_2$), 6.68 (d, 2H, H $_o$ -C, J = 7.85 Hz), 7.21 (d, 2H, H $_m$ -C, J = 7.44 Hz), 7.30 (t, 2H, H $_p$ -A, J = 7.03 Hz), 7.45 (s, 1H, H $_o$ -C), 7.47 (t, 2H, H $_m$ -A, J = 7.24 Hz), 7.53 (d, 2H, H $_o$ -B, J = 7.86 Hz), 7.82 (d, 2H, H $_m$ -B, J = 7.86 Hz), 7.88 (d, 2H, H $_o$ -A, J = 7.65 Hz), 8.37 (s, 1H, H-5) ppm. ^{13}C NMR (100 MHz, DMSO- d_6) δ 20.9 (C-COCH $_3$), 41.3 (C-4'), 51.9 (C-5'), 101.5 (C-CH $_2$), 108.3 (C $_o$ -C), 118.2 (C $_o$ -A), 121.8 (C $_m$ -C), 123.6 (C-4), 126.3 (C $_p$ -A), 126.7 (C-5), 128.6 (C $_o$ -B), 129.4 (C $_m$ -A), 129.7 (C $_m$ -B), 131.7 (C $_p$ -B), 132.7 (C $_i$ -B), 139.2 (C $_i$ -A), 145.3 (C $_m$ -C), 147.7 (C $_i$ -C), 148.2 (C-3), 149.0 (C $_p$ -C), 153.6 (C-3'), 167.5 (C=O) ppm. MS (70 eV) m/z (%): 484 (86, M $^+$), 442 (100), 294 (25), 77 (20). Anal. Calcd for C $_{27}$ H $_{21}$ ClN $_4$ O $_3$: C, 66.87; H, 4.36; N, 11.55. Found: C, 66.80; H, 4.36; N, 11.58.

Acknowledgments

The authors wish to credit The Developmental Therapeutics Program (DTP) of the National Cancer Institute of the United States (US) for performing the screening of compounds. This work was supported financially by Colciencias, Universidad del Valle, Consejería de Innovación, Ciencia y Empresa (Junta de Andalucía, Spain) and The Universidad de Jaén. Authors thank 'Servicios Técnicos de Investigación de la Universidad de Jaén' and the staff for data collection.

References and notes

- Ko, H. H.; Tsao, L. T.; Yu, K. L.; Liu, C. T.; Wang, J. P.; Lin, C. N. *Bioorg. Med. Chem.* **2003**, *11*, 105.
- Matsuda, H.; Morikawa, T.; Ando, S.; Iwao, T.; Masayuki, Y. *Bioorg. Med. Chem.* **2003**, *11*, 1995.
- Herencia, F.; Ferrandiz, M. L.; Ubieda, A.; Dominguez, J. N.; Charris, J. E.; Lobo, G. M.; Alcaraz, M. J. *Bioorg. Med. Chem. Lett.* **1998**, *8*, 1169.
- Ducki, S.; Forrest, R.; Hadfield, J. A.; Kendall, A.; Lawrence, N. J.; McGown, A. T.; Rennison, D. *Bioorg. Med. Chem. Lett.* **1998**, *8*, 1051.
- Nielsen, S. F.; Christensen, S. B.; Cruciani, G.; Kharazmi, A.; Liljefors, T. *J. Med. Chem.* **1998**, *41*, 4819.
- Parmer, V. S.; Sharma, N. K.; Husain, M.; Watterson, A. C.; Kumar, J.; Samuelson, L. A.; Ashok, L. C.; Prasad, A. K.; Kumar, A.; Malhotra, S.; Kumar, N.; Jha, A.; Singh, A.; Singh, I.; Himanshu, V. A.; Shakil, N. A.; Tripathi, S.; Mukherjee, S.; Sharma, S. K.; Singh, S. K.; Kumar, A.; Jha, H. N.; Olsen, C. E.; Stove, C. P.; Bracke, M. E.; Mareel, M. M. *Bioorg. Med. Chem.* **2003**, *11*, 913.
- Mukherjee, S.; Kumar, V.; Prasad, A. K.; Raj, H. G.; Bracke, M. E.; Olsen, C. E.; Jain, S. C.; Parmar, V. S. *Bioorg. Med. Chem.* **2001**, *9*, 337.
- Lin, Y. M.; Zhou, Y.; Flavin, M. T.; Zhou, L. M.; Nie, W.; Chen, F. C. *Bioorg. Med. Chem.* **2002**, *10*, 2795.
- Lopez, S. N.; Castelli, M. V.; Zaccchino, S. A.; Dominguez, J. N.; Lobo, G.; Jaime, C. C.; Cortes, J. C. G.; Ribas, J. C.; Devia, C.; Ana, M. R.; Ricardo, D. E. *Bioorg. Med. Chem.* **2001**, *9*, 1999.
- Li, R.; Kenyon, G. L.; Cohen, F. e.; Chen, X.; Gong, B.; Dominguez, J. N.; Davidson, E.; Kurzban, G.; Millar, R. E.; Nuzum, E. O.; Rosenthal, P. J.; Mckerrrow, J. H. *J. Med. Chem.* **1995**, *38*, 5031.
- Liu, M.; Wilairat, P.; Go, M. L. *J. Med. Chem.* **2001**, *44*, 4443.

12. Go, M. L.; Wu, X.; Liu, X. L. *Curr. Med. Chem.* **2005**, *12*, 483.
13. Johnson, M.; Younglove, B.; Lee, L.; LeBlanc, R.; Holt, H.; Hills, P.; Mackay, H.; Brown, T.; Mooberry, L. S.; Lee, M. *Bioorg. Med. Chem.* **2007**, *17*, 5897.
14. Ramana, M. V.; Billa, V. K.; Pallela, V. R.; Muralidhar, R. M. R.; Boominathan, R.; Gabriel, J. L.; Reddy, E. P. *Bioorg. Med. Chem.* **2008**, *16*, 3907.
15. Bhat, A. R.; Athar, F.; Azam, A. *Eur. J. Med. Chem.* **2009**, *44*, 926.
16. Ozdemir, Z.; Kandilci, H. B.; Gumusel, B. H.; Calis, U.; Bilgin, A. A. *Eur. J. Med. Chem.* **2006**, *42*, 373.
17. Ozdemir, A.; Zitouni, G. T.; Kaplancikli, Z. A.; Revial, G.; Guven, K. *Eur. J. Med. Chem.* **2007**, *42*, 403.
18. Milano, J.; Oliveira, S. M.; Rossato, M. F.; Sauzem, P. D.; Machado, P.; Beck, P.; Zanatta, N.; Martins, M. A. P.; Mello, C. F.; Rubin, M.; Ferreira, J.; Bonacorso, H. G. *Eur. J. Pharmacol.* **2008**, *581*, 86.
19. Carrión, M. D.; Luisa, C.; López, L. C.; Camacho, M. E.; Tapias, V.; Escames, G.; Castroviejo, D. A.; Espinosa, A.; Gallo, M. A.; Entrena, A. *Eur. J. Med. Chem.* **2008**, *43*, 2579.
20. Loupy, A.; Petit, A.; Hamelin, J.; Texier-Boullet, F.; Jacquault, P.; Mathe, D. *Synthesis* **1998**, 1213.
21. Varma, R. S. *Green Chem.* **1999**, *1*, 43.
22. Deshayes, S.; Liagre, M.; Loupy, A.; Luche, J.-L.; Petit, A. *Tetrahedron* **1999**, *55*, 10851.
23. Tanaka, K.; Toda, F. *Chem. Rev.* **2000**, *100*, 1025.
24. Varma, R. S. *Clean Prod. Processes* **1999**, *1*, 132.
25. Varma, R. S. *Pure Appl. Chem.* **2001**, *73*, 193.
26. Azizian, J.; Karimi, A. R.; Kazemizadeh, Z.; Mohammadi, A. A.; Mohammadizadeh, M. R. *J. Org. Chem.* **2005**, *70*, 1471.
27. Kidwai, M.; Mothsra, P. *Synth. Commun.* **2006**, *36*, 817.
28. Zhang, T. S.; Zhang, Y.; Jiang, J.; Jia, B.; Zhang, R.; Ji, J. *Synlett* **2006**, 2785.
29. Kira, M. A.; Abdel-Raeman, M. O.; Gadalla, K. Z. *Tetrahedron Lett.* **1969**, *10*, 109.
30. Boyd, M. R.; Paull, K. D. *Drug Dev. Res.* **1995**, *34*, 91.
31. Hubbard, W. C.; Alley, M. C.; Gray, G. N.; Green, K. C.; McLemore, T. L.; Boyd, M. R. *Cancer. Res.* **1989**, *49*, 826.
32. Monks, A. P.; Scudiero, D. A.; Skehan, P.; Shoemaker, R. H.; Paull, K. D.; Vistica, C.; Hose, C.; Langley, J.; Cronise, P.; Vaigro-Wolff, A.; Gray-Goodrich, M.; Campbell, H.; Mayo, M.; Boyd, M. *J. Natl. Cancer Inst.* **1991**, *83*, 757.
33. Weinstein, J. N.; Myers, T. G.; O'Connor, P. M.; Friend, S. H.; Fornace, A. J., jr; Kohn, K. W.; Fojo, T.; Bates, S. E.; Rubinstein, L. V.; Anderson, N. L.; Buolanwini, J. K.; van Osdol, W. W.; Monks, A. P.; Scudiero, D. A.; Sausville, E. A.; Zaharevitz, D. W.; Bunow, B.; Viswanadhan, V. N.; Jhonson, G. S.; Wittes, R. E.; Paull, K. D. *Science* **1997**, *275*, 343.